Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Shrink Nanotechnologies, Inc.ex321.htm
EX-31.1 - EXHIBIT 31.1 - Shrink Nanotechnologies, Inc.ex311.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q/A
Amendment No 2.

[X]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010

[  ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _____________

Commission File Number: 000-52860
 

 Shrink Nanotechnologies, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
20-2197964
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
4100 Calit2 Bldg
Irvine, CA 92697-2800
4100 Calit2 Bldg
Irvine, CA 92697-2800
________________________________________________________________
(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code:                                                    (760) 804-8844
Securities registered pursuant to Section 12(b) of the Act:                                            None
Securities registered pursuant to Section 12(g) of the Act:                                            $.001 par value common stock

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes x     No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x     No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company:

Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o     No x
 
APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date.

There were a total of 200,345,163 shares of the registrant’s common stock outstanding as of May 23, 2011.



 
 

 

 
SHRINK NANOTECHNOLOGIES, INC.
FORM 10-Q/A
EXPLANATORY NOTE
 
This Second Amended Form 10-Q (“Second Amended Report”) of Shrink Nanotechnologies, Inc.  for the period ended September 30, 2010, amends and restates our originally filed Form 10-Q which was originally filed on November 15, 2010 and amended by our filing of Amendment No. 1 on Form 10-Q/A, which was filed on November 29, 2010 (collectively, as amended and restated prior to the filing hereof,  the “Previous Report”).
 
This Second Amended Report is being filed for the purpose of restating certain amounts in Item 1, Financial Statements, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Item 4, Controls and Procedures, as well as for currently dated certifications from the company’s principal executive officer and principal financial officer as required by Section 302 and 906 of the Sarbanes-Oxley Act of 2002. The certifications of the Company’s principal executive officer and principal financial officer are attached to this Second Amended Report as Exhibits 31.1 and 32.1.
 
The Company’s 2010 financial statements included in the Original Report, as amended, were prepared reflecting a prepaid expense asset associated with a $270,000 signature bonus in an amended operating agreement with BCGU, LLC (the “Signature Bonus”) and its subsequent expense accretion.  The Company became aware of the error with respect to the historical accounting associated with the Signature Bonus as a prepaid expense and its subsequent expense accretion during its preparation for the 2010 audit.  The Company’s management determined that the Signature Bonus should have been immediately expensed at the agreement’s effective date, October 1, 2009 and all subsequent expense accretions reversed.  
 
 
This restatement reduces net loss for the three months and nine months ended September 30, 2010 by $22,500, and $67,500, respectively.   $180,000 of prepaid expenses have been removed from the balance sheets at September 30, 2010.
 
These restatements relate to non-cash entries in the 2010 financial statements including the consolidated statement of cash flows by a change in prepaid expenses.
 
The Form 10-Q/A also reclassifies approximately $514,667 of related party payables from its balance sheet line item “Accounts payable and accrued expense” to “Due to related parties,” to better characterize the nature of the liability.
 
 
The adjustments made as a result of the Restatement are specifically discussed in this Second Amended Report in Note 2.  “Restatement of Financial Statements”, of the Notes to Consolidated Financial Statements.
 
This Second Amended Report provides disclosure as at September 30, 2010, and does not, and is not intended to,   reflect events or disclosure occurring after the filing of the Original Report, other than the restatement for the matter discussed above.  Moreover, the Company has terminated one of its hallmark licenses, and has undergone significant business and other changes since the date of the Original Report.  Accordingly, this Second Amended Report should not be viewed as current information and should be considered only in conjunction with more recent reports and events.   Such reports include, among other things, the events described in the company’s current reports on Form 8-K and Forms 10-Q and Annual Report on Form 10-K for the year ended December 31, 2010, each as may be amended or supplemented from time to time, all of which reflect events and information after the date of the Original Report. The financial statements of the Company for the year ended December 31, 2009 have been restated and are reflected in our Annual Report on Form 10-K for the year ended December 31, 2010.  Contemporaneously with the Second Amended Report, the Company will file an amended Form 10-Q for the first and second quarters of 2010.
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
SHRINK NANOTECHNOLOGIES, INC.
 
SEPTEMBER 30, 2010 FORM 10-Q QUARTERLY REPORT
 
INDEX
  
Page
   
Forward Looking Statements
ii
 
Use of Terms
ii
   
PART I - FINANCIAL INFORMATION
F-1
   
Item 1. - Financial Statements
F-1
Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations
1
   
Item 4 - Controls and Procedures
17
   
PART II - OTHER INFORMATION
 
   
Item 1 -   Legal Proceedings
18
   
Item 1A – Risk Factors
18
   
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds
29
   
Item 3 - Defaults Upon Senior Securities
29
   
Item 4 - Submission of Matters to a Vote of Security Holders
29
   
Item 5 - Other Information
29
   
Item 6 – Exhibits
30

 
 
 
 
 



 
i

 


Forward Looking Statements

Certain information contained in this Quarterly Report on Form 10-Q (this “Report” or “Quarterly Report”) includes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”).  These statements are expressed in good faith and based upon what we believe are reasonable assumptions, but there can be no assurance that these expectations will be achieved or accomplished.  These forward looking statements can be identified by the use of terms and phrases such as “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect,” and the like, and/or future-tense or conditional constructions (“will,” “may,” “could,” “should,” etc.).

The statements herein, which are not historical, reflect our current expectations and projections about the Company’s future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to the Company and management and their interpretation of what are believed to be significant factors affecting the businesses, including many assumptions regarding future events.  Such forward-looking statements include statements regarding, without limitation:

·  
the development, commercialization and market acceptance of our recently acquired microfluidic, “shrinkable plastic” or “structured” cell culturing devices (StemDisc™) and solar concentrator technologies, and other related technologies stemming from our core technologies, and the global related costs to bringing these technologies and products to market,
 
·  
our ability to continue funding under our various funding agreements with universities under the California Regents as well as other research and development relationships we have and may enter into,
 
·  
our immediate and growing need to raise the capital needed or obtain government or educational grants to implement our business plan,
 
·  
our ability to innovate using our existing platform technology, a shrinkable plastic material branded as “NanoShrink™” and to find new market accepted uses for the same (such as in the printed electronics industry),
 
·  
the relative efficiencies of the solar concentrator technologies we are developing, including our future ability to produce concentrators that produce power at a commercially compelling  dollar-per-watt rate,
 
·  
our ability to secure economical component and manufacturing sourcing for the various businesses we seek to engage in,
 
·  
our ability to secure certain critical licenses from third parties,  some of which  may be potential commercial competitors for one or more of our products,
 
·  
the progress of our research and development activities,
 
·  
our ability to further acquire, hold and defend our intellectual property or to fund our license agreements with the California Regents,
 
·  
the demand for printed “high” technologies (electronics, microfluidics and the like),
 
·  
the projected growth in stem cell research and public policy changes relating to government funding of the same,
 
·  
the outcome of contentious litigation in federal courts related to human embryonic stem cell culturing and development (see Shirley v. Sebilus),
 
·  
alternative energy demands (specifically, products ultimately derived from our solar concentrator technology) , and
 
·  
the presumed size and growth of the market for lab-on-a-chip devices in life sciences.
 
These forward looking statements should be considered in addition to our risk factors (contained in this Report under the heading “Item 1A Risk Factors” below).  Additional risks not described above, or unknown to us, may also adversely affect the Company or its results.

Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report.  We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the filing date of this Quarterly Report, other than as may be required by applicable law or regulation.  Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the SEC (which shall also include  all Form 10-Ks, Form 10-Qs, Form 8-Ks proxy and information statements, and other periodic reports filed by us in the SEC’s EDGAR filing system (www.sec.gov) each, as amended from time to time) which attempt to update interested parties of the risks and factors and other disclosures that may affect our business, financial condition, results of operation and cash flows.
 
Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the Risk Factors section in this Quarterly Report.

Use of Terms
 
Except as otherwise indicated by the context, references in this report to (i) the “Shrink Parent” or “Parent” or similar terms refer to the publicly traded parent holding company and registrant, Shrink Nanotechnologies, Inc., a Delaware corporation,  (ii)  the “Company”, “we”, “us”, or “our”, refer to the combined business of Shrink Parent, together with its wholly owned subsidiaries, Shrink Technologies, Inc., ShrinkChips, LLC and Shrink Solar, LLC, unless the context requires otherwise, (iii) “Shrink” refers to Shrink Technologies, Inc., a California corporation acquired by us in May 2009, inclusive of its R&D activities through universities or third parties; and “Shrink Chips” and “Shrink Solar” refer to our recently organized Delaware subsidiaries ShrinkChips LLC and Shrink Solar LLC, (iv) “Forward Split” refers to the 5 for 1 forward split of the Parent’s stock effective as of April 8, 2010, (v) “SEC” are to the United States Securities and Exchange Commission, (vi) “Securities Act” are to Securities Act of 1933, as amended, and (vii) “Exchange Act” are to the Securities Exchange Act of 1934, as amended.

All references herein to share amounts and pricing information contained in this Report are as adjusted to give effect to the recent Forward Split
 
 

 
ii

 
 
 
Item 1.  Financial Statements
 
 
SHRINK NANOTECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED - BALANCE SHEETS
(Unaudited)
             
       
September 30,
 
December 31,
       
2010
 
2009
       
(restated)
   
ASSETS
       
             
Current assets
       
 
Cash
$
2,932
$
58,539
 
Litigation receivable, discontinued operations
 
-
 
108,011
 
Other Receivable
 
10,000
 
-
 
Prepaid expenses
 
769,929
 
130,241
   
Total current assets
 
782,861
 
296,791
             
Prepaid expenses, non-current
 
68,355
 
-
Property, plant and equipment, net
 
105,229
 
140,054
Intangible assets, net
 
267,687
 
219,062
             
   
TOTAL ASSETS
$
1,224,132
$
655,907
             
LIABILITIES AND STOCKHOLDERS' DEFICIT
       
             
Current liabilities
       
 
Accounts payable and accrued expenses
$
778,544
$
631,840
 
Due to former preferred stock shareholders
 
-
 
143,825
 
Due to a related party
 
525,417
 
354,500
 
Convertible debentures, net of discount
 
402,101
 
13,611
 
Convertible debentures, net of discount, default - related party
 
218,121
 
218,121
   
Total current liabilities
 
1,924,183
 
1,361,897
             
   
TOTAL LIABILITIES
 
1,924,183
 
1,361,897
             
COMMITMENTS
       
             
STOCKHOLDERS' DEFICIT
       
 
Preferred stock, 25,000,000 shares authorized, $0.001 par value
       
   
issued and outstanding 20,000,000 and 20,000,000
       
   
at September 30, 2010 and December 31, 2009 respectively
 
20,000
 
20,000
 
Common stock, 475,000,000 shares authorized, $0.001 par value
       
   
issued and outstanding 192,906,182 and 172,921,485
       
   
at September 30, 2010 and December 31, 2009, respectively
 
192,907
 
172,921
 
Additional paid in capital
 
5,051,001
 
914,784
 
Accumulated deficit
 
(5,963,959)
 
(1,813,695)
   
TOTAL STOCKHOLDERS' DEFICIT
 
(700,051)
 
(705,990)
             
   
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
$
1,224,132
$
655,907
             
The accompanying notes are an integral part of these financial statements
 
 
 
 
 
F-1

 
 
 
 
 
SHRINK NANOTECHNOLOGIES, INC.
(A Development Stage Company)
 CONSOLIDATED - STATEMENTS OF OPERATIONS
(Unaudited)
                     
From Inception
     
For the three months
 
For the three months
 
For the nine months
 
For the nine months
 
January 15, 2008
     
September 30,
 
September 30,
 
September 30,
 
September 30,
 
through September 30,
     
2010
 
2009
 
2010
 
2009
 
2010
     
(restated)
     
(restated)
     
(restated)
Revenues:
                   
 
Revenues, net
$
-
$
-
$
-
$
-
$
-
 
Cost of sales
 
-
 
-
 
-
 
-
 
-
Gross Profit
 
-
 
-
 
-
 
-
 
-
                       
Expenses
                   
 
Research and development
 
32,777
 
-
 
165,918
 
73,554
 
367,686
 
Professional fees
 
26,152
 
50,332
 
110,815
 
97,679
 
261,931
 
General and administrative
 
993,886
 
537,977
 
3,341,155
 
811,269
 
4,762,600
 
Depreciation and amortization
 
36,612
 
12,733
 
68,908
 
17,009
 
99,390
Total operating expenses
 
1,089,427
 
601,042
 
3,686,796
 
999,511
 
5,491,607
                       
Loss from operations
 
(1,089,427)
 
(601,042)
 
(3,686,796)
 
(999,511)
 
(5,491,607)
                       
Other Income (Expense)
                   
 
Interest expense
 
(186,711)
 
(17,550)
 
(463,468)
 
(31,636)
 
(498,056)
 
Loss from extinguishment of debt
 
-
 
-
 
-
 
-
 
(118,121)
Total Other Income (Expense)
 
(186,711)
 
(17,550)
 
(463,468)
 
(31,636)
 
(616,177)
                       
Net loss from continued operations
 
(1,276,138)
 
(618,592)
 
(4,150,264)
 
(1,031,147)
 
(6,107,783)
                       
Discontinued Operations
                   
 
Gain from discontinued operations of Audiostocks business
 
-
 
-
 
-
 
-
 
143,825
Income (loss) from discountinued operations
 
-
 
-
 
-
 
-
 
143,825
(Loss) Before Income Taxes
 
(1,276,138)
 
(618,592)
 
(4,150,264)
 
(1,031,147)
 
(5,963,959)
                       
Income Taxes
 
-
 
-
 
-
 
-
 
-
                       
NET (LOSS)
$
(1,276,138)
$
(618,592)
$
(4,150,264)
$
(1,031,147)
$
(5,963,959)
                       
Net income (loss) per common share, basic and diluted:
                   
 
Net (loss) from continued operations
 
(0.01)
 
(0.00)
 
(0.02)
 
(0.01)
 
-
 
Net income from discontinued operations
 
-
 
-
 
-
 
-
 
-
Net (loss) per common share:
$
(0.01)
$
(0.00)
$
(0.02)
$
(0.01)
$
-
                       
Weighted average common and common equivalent shares outstanding
               
 
Basic and diluted
 
192,781,409
 
166,409,750
 
186,583,602
 
99,568,530
 
110,752,513
                       
The accompanying notes are an integral part of these financial statements



 
F-2

 


SHRINK NANOTECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED - STATEMENTS OF CASH FLOWS
(Unaudited)
               
             
From Inception
     
For the nine months
 
For the nine months
 
January 15, 2008
     
September 30,
 
September 30,
 
through September 30,
     
2010
 
2009
 
2010
     
(restated)
     
(restated)
               
CASH FLOWS FROM OPERATING ACTIVITIES
           
 
  Net loss
$
(4,150,264)
$
(1,031,147)
$
(5,963,959)
               
 
Adjustments to reconcile net earnings to net cash used
           
 
by operating activities:
           
 
     Depreciation and amortization
 
68,908
 
17,009
 
99,390
 
     Debt discount accretion
 
387,322
 
21,568
 
400,933
 
     Non-cash share-based payments
 
2,771,141
 
518,037
 
3,310,940
 
     Loss from extinguishment of debt
 
-
 
-
 
118,121
 
Changes in assets and liabilities, net of effects from acquisitions
       
 
     Prepaid expenses
 
123,186
 
(223,150)
 
(7,055)
 
     Accounts receivable
 
98,011
 
(4,790)
 
(8,328)
 
     Accounts payable and accrued liabilities
 
173,795
 
416,175
 
1,078,108
NET CASH USED IN OPERATING ACTIVITIES
 
(527,900)
 
(286,298)
 
(971,849)
               
CASH FLOWS FROM INVESTING ACTIVITIES
           
 
     Cash purchased at acquisition
 
-
 
62,404
 
62,404
 
     Additions to fixed assets
 
-
 
(13,535)
 
(16,113)
 
     Additions to intangible assets
 
(82,707)
 
(106,033)
 
(205,105)
NET CASH FROM INVESTING ACTIVITIES
 
(82,707)
 
(57,164)
 
(158,814)
               
CASH FLOWS FROM FINANCING ACTIVITIES
           
 
     Proceeds from subsidiary prior to merger
 
-
 
12,500
 
12,500
 
     Proceeds from issuance of common stock
 
-
 
355,000
 
355,001
 
     Proceeds from convertible debentures
 
555,000
 
20,000
 
766,094
NET CASH FROM FINANCING ACTIVITIES
 
555,000
 
387,500
 
1,133,595
               
NET CHANGE IN CASH
 
(55,608)
 
44,038
 
2,932
CASH BALANCES
           
 
  Beginning of period
 
58,539
 
37,940
 
-
 
  End of period
$
2,932
$
81,978
$
2,932
               
SUPPLEMENTAL DISCLOSURE:
           
 
  Interest paid
$
437
$
125
$
-
 
  Income taxes paid
$
-
$
-
$
-
               
NON-CASH INVESTING AND FINANCING TRANSACTIONS :
           
 
Stock based prepaid expenses
$
831,229
$
-
$
-
               
The accompanying notes are an integral part of these financial statements
 
 
 
 
F-3

 
 
SHRINK NANOTECHNOLOGIES, INC.
Notes to the Consolidated Financial Statements
For the nine months ended September 30, 2010
(Unaudited)
 
NOTE 1.  BASIS OF PRESENTATION AND NATURE OF BUSINESS
 
Shrink Nanotechnologies, Inc. (the “Company or the “Successor Entity” or “us” or “we”) is a development stage company  that is dedicated to the commercial adoption of a nanotechnology platform called the ShrinkChip Manufacturing Solution™. We believe this platform represents a new paradigm in the rapid design and low-cost fabrication of diagnostic chips and other nano-size devices that we intend to commercialize as measuring tools and energy and content transfer devices for a wide range of applications from the life sciences, drug and chemical analysis industries to the optoelectronics components and renewable energy businesses.

The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation have been included.  Operating results for the nine months ended September 30, 2010 are not necessarily indicative of the results that may be expected for the year ended December 31, 2010.  For further information, refer to the Company’s financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2009.

NOTE 2.     RESTATED FINANCIAL STATEMENTS

The Company’s financial statements for the period ended September 30, 2010 have been restated to record $270,000 of expenses related to the BCGU, LLC Amended Operating Agreement Signature Bonus (the “Signature Bonus”) at the effective date of the Amended Operating Agreement, October 1, 2009 and remove $270,000 in prepaid expenses at October 1, 2009.  The Company has also reversed the subsequent expense accruals related to the prepaid balance.  The Restatement was due to an error resulting from the Company’s failure to properly recognize expenses in the appropriate period.  The Company determined that all of the services provided by BCGU, LLC related to the Signature Bonus had been provided immediately at the time of the agreement effective date and that there were no provisions found in the agreement that allowed the Company any type of recourse related to that amount.  The prepaid expense asset related to the Signature Bonus previously recorded for the period at September 30, 2010 has been removed in these restated financial statements.

The Company has also reclassifies amounts due to BCGU, LLC and Business Consulting Group Unlimited, Inc. from the line item “Accounts payable and accrued expenses” to “Due to related parties” on the Balance Sheets, to better characterize the nature of the liability.

The following summarized financial statements compare of the Company’s original and restated financial statements.

SHRINK NANOTECHNOLOGIES, INC.
(A Development Stage Company)
CONSOLIDATED - BALANCE SHEETS
(Unaudited)
       
September 30,
 
September 30,
       
2010
 
2010
       
Original
 
Restated
ASSETS
       
             
Current assets
       
 
Cash
$
2,932
$
2,932
 
Other receivable
 
10,000
 
10,000
 
Prepaid expenses
 
859,929
 
769,929
   
Total current assets
 
872,861
 
782,861
             
Prepaid expenses, non-current
 
158,355
 
68,355
Property, plant and equipment, net
 
105,229
 
105,229
Intangible assets, net
 
267,687
 
267,687
             
   
TOTAL ASSETS
$
1,404,132
$
1,224,132
             
LIABILITIES AND STOCKHOLDERS' DEFICIT
       
             
Current liabilities
       
 
Accounts payable and accrued expenses
$
1,293,211
$
778,544
 
Due to a related party
 
10,750
 
525,417
 
Convertible debentures, net of discount
 
402,101
 
402,101
 
Convertible debentures, net of discount, default - related party
 
218,121
 
218,121
   
Total current liabilities
 
1,924,183
 
1,924,183
             
   
TOTAL LIABILITIES
 
1,924,183
 
1,924,183
             
STOCKHOLDERS' DEFICIT
       
 
Preferred stock, 25,000,000 shares authorized, $0.001 par value
       
   
issued and outstanding 20,000,000 at December 31, 2009
 
20,000
 
20,000
 
Common stock, 475,000,000 shares authorized, $0.001 par value
     
-
   
issued and outstanding 172,921,485 at December 31, 2009
 
192,907
 
192,907
 
Additional paid in capital
 
5,051,001
 
5,051,001
 
Accumulated deficit
 
(5,783,959)
 
(5,963,959)
   
TOTAL STOCKHOLDERS' DEFICIT
 
(520,051)
 
(700,051)
             
   
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
$
1,404,132
$
1,224,132
             

 
 
 
F-4

 
 

SHRINK NANOTECHNOLOGIES, INC.
(A Development Stage Company)
 CONSOLIDATED - STATEMENTS OF OPERATIONS
(Unaudited)
                   
     
For the three months
 
For the three months
 
For the nine months
 
For the nine months
     
ended September 30,
 
ended September 30,
 
ended September 30,
 
ended September 30,
     
2010
 
2010
 
2010
 
2010
     
Original
 
Restated
 
Original
 
Restated
Total operating expenses
 $
1,111,927
$
1,089,427
$
3,754,296
$
3,686,796
                   
Loss from operations
 
(1,111,927)
 
(1,089,427)
 
(3,754,296)
 
(3,686,796)
                   
Total Other Income (Expense)
 
(186,711)
 
(186,711)
 
(463,468)
 
(463,468)
                   
(Loss) Before Income Taxes
 
(1,298,638)
 
(1,276,138)
 
(4,217,764)
 
(4,150,264)
                   
Income Taxes
 
-
 
-
 
-
 
-
                   
NET (LOSS)
 $
(1,298,638)
$
(1,276,138)
$
(4,217,764)
$
(4,150,264)
                   
Net (loss) per common share:
 $
(0.01)
$
(0.01)
$
(0.02)
$
(0.02)
 
NOTE 3.                   GOING CONCERN

The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  Because of the recurring operating losses, no revenues and the excess of current liabilities over current assets, there is substantial doubt about the Company’s ability to continue as a going concern.  

As a result of the aforementioned conditions the Company may be unable to meet certain obligations to fund future research and development activities.  The Company’s continuation as a going concern is dependent on obtaining additional outside financing, as it is not anticipated that the Company will have profitable operations from its research and development activities during the near term.  The Company has funded losses from its research and development and other operations primarily from the issuance of debt and equity.  The Company believes that the issuance of equity and debt will continue to fund operating losses in the short-term until the Company can generate revenues sufficient to fund its operations.  If management can’t achieve its plans there is a possibility that operations will discontinue.

NOTE 4.  INCOME TAXES

Income tax expense is provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes.  Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes.  The differences relate primarily to the effects of net operating loss carry forwards and differing basis, depreciation methods, and lives of depreciable assets. The deferred tax assets represent the future tax return consequences of those differences, which will be deductible when the assets are recovered.
 
No income tax benefit (expense) was recognized for the nine months ended September 30, 2010 as a result of tax losses in this period and because deferred tax benefits, derived from the Company’s prior net operating losses, were previously fully reserved and the Company has cumulative net operating losses for tax purposes in excess of $4 million.
 
The Company and  its subsidiaries currently have tax return periods open beginning with December 31, 2006 through December 31, 2009.
 
 
 
F-5

 

 
NOTE 5.   RECENT ACCOUNTING PRONOUNCEMENTS

Recently Adopted Accounting Policies

In January 2010, the FASB issued amended guidance on fair value measurements and disclosures. The new guidance requires additional disclosures regarding fair value measurements, amends disclosures about postretirement benefit plan assets, and provides clarification regarding the level of disaggregation of fair value disclosures by investment class. This guidance is effective for interim and annual reporting periods beginning after December 15, 2009, except for certain Level 3 activity disclosure requirements that will be effective for reporting periods beginning after December 15, 2010. Accordingly, we adopted this amendment effective January 1, 2010, except for the additional Level 3 requirements which will be adopted in 2011.

Not Yet Adopted

In March 2010, the Financial Accounting Standards Board (FASB) ratified Emerging Issues Task Force (EITF) guidance related to Revenue Recognition that applies to arrangements with milestones relating to research or development deliverables. This guidance provides criteria that must be met to recognize consideration that is contingent upon achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. This guidance is effective for us January 1, 2011 and is not expected to have a material impact to our consolidated financial position or results of operations.

NOTE 6.   INTANGIBLE ASSETS

Intangible assets consist of intellectual property rights of an exclusive license to several patent pending inventions surrounding our core technologies.   Goodwill and other intangible assets are required to be tested at least on an annual basis for impairment or on an interim basis if an event occurs or circumstances change that would reduce the fair value of a reporting unit below its carrying value. The fair value of definite lived intangible assets is determined by using a “relief from royalty” approach.  Intangible assets with estimable useful lives and those assets with defined lives due to the legal nature of the asset are amortized over their estimated useful lives, 15 years, using the straight-line method.

Intangible assets consisted of the following at:

   
September 30,
 
December 31,
   
2010
 
2009
Intangible Assets, net:
       
   Patents
$
177,754
$
98,559
License
 
112,902
 
112,902
Trademarks
 
14,450
 
10,938
  Amortization
 
(37,419)
 
(3,336)
 
$
267,687
$
219,063


To date, the Company has not utilized its current patents to manufacture products/parts for sale, testing and evaluation.  When/if we do begin to mass produce products we will re-evaluate our amortization practice related to these patents.  During the nine months ended September 30, 2010 and 2009 the Company recorded $34,083 and $1,523 in amortization expenses, respectively.   At this time, estimated future amortization for the balance of this fiscal year is expected to be approximately $37,000 and amortization of the following amounts for the fiscal years ended on December 31 are expected to be as follows

For the year ending
 
Amount
2011
$
10,360
2012
 
10,390
2013
 
10,360
2014
 
10,310
After 12/31/2014
 
223,607
 
 

 
 
F-6

 
NOTE 7.   PREPAID EXPENSES

Current prepaid expenses consisted of the following at:

   
September 30,
 
December 31,
   
2010
 
2009
   
(restated)
   
Prepaid stock based consultant fees
$
762,874
$
120,333
Other prepaid expenses
 
7,055
 
9,908
Total Current Prepaid Expenses
$
769,929
$
130,241


Non-current prepaid expenses consisted of the following at:

   
September 30,
 
December 31,
   
2010
 
2009
   
(restated)
   
Prepaid stock based consultant fees
$
68,355
$
-
Total Non-current Prepaid Expenses
 
68,355
$
-


NOTE 8.  RESEARCH AND LICENSE AGREEEMENTS

Sponsored Research Agreement with UC Regents (May 2010)

During  May,  2010, Shrink entered into the Sponsored Research Agreement (or, the “SRA Agreement”) with UC Regents on behalf of the Irvine campus (“UCI”).  The SRA Agreement is for a term of three years or such time as the research is completed, whichever is longer. The SRA Agreement may be terminated by the Company subject to satisfying appropriate notice requirements required under the agreement.

The SRA Agreement provides, among other things, that the Company will sponsor specified research relating to development of (i) integrated, manufacturable, nanostructured substrates for biosensing and testing of new bioassays as well as assessing viability of other shrinkable materials, and (ii) stem cell tools that use shrinkable plastic microfluidic technologies, each as more fully provided in the SRA Agreement.  The SRA Agreement provides that the Company shall sponsor the research costs up to a budget of $632,051, of which $20,000 has been paid to the California Regents.  We have exclusive access to license intellectual property from the SRA Agreement beginning from July 1, 2009 forward according to the terms of the SRA Agreement.

The Company’s research sponsorship obligations require it to provide funding (which may be from the Company or other third parties) totaling $632,051 during the three year term of the SRA Agreement.  Of this amount $202,796 shall be paid during the 12 month period ended April 30, 2011; $211,311 shall be paid during the 12 month period ended April 30, 2012; and the remaining $217,944 shall be paid during the 12 month period ended April 30, 2013.  The foregoing payments are to be paid in quarterly installments of ¼ of the total cash fees payable during such 12 month period.

In the event that research under the SRA Agreement yields additional inventions and intellectual property, we have the right to enter into an additional exclusive license agreement with the UC Regents.  In order to exercise its rights, we must not be in default of any payment or funding obligation under the SRA Agreement and, must notify the UC Regents of its intent to license the additional intellectual property within nine (9) months of receipt of notice from the UC Regents of the invention.  In addition, among other conditions and limitations, we would be required to pay for patent application and filing costs relating to additional patents licenses and, to prosecute its rights as against third parties.
 
 
 
F-7

 

 
The license we have the right to enter into under the SRA Agreement, is substantially similar to the previously disclosed license rights we have with the UC Regents above, except that we are not required to pay an initial license issue fee, or initial legal fee reimbursement of $35,000, and the terms of the annual license fee has changed to a fee of $5,000 for rights to each patent license acquired by us, with an overall license maintenance fee of $10,000 per annum commencing the fourth year after entry into the license (the “License Date”).  In addition, we are required to pay a fee of 30% of certain income generated from third party sublicenses of the additional intellectual property we license as well as royalty payments of:

·  
2.5% of net sales where the first sale occurs within three years after the License Date;
·  
4% of net sales where the first sale occurs between three and six years after the License Date;
·  
and 5% of net sales where the first sale occurs beyond six years after the License Date.  
·  
In each case, the minimum earned royalty payment paid shall be $15,000 commencing the year of the first commercial sale of the licensed technology, subject to increase, if and as we expand the SRA License to include additional patents from time to time.  
 
 NOTE 9.  COMMITMENTS AND LEASES – RELATED PARTY
 
The Company previously shared office space with the Noctua Fund Manager, LLC, which is affiliated with two of our directors.  On January 1, 2009 we began accruing a $2,500 rental expense each month for the use of the space.  From January 1, 2009 to May 28, 2009 there was not a written agreement; there was simply a verbal agreement between the two companies.  The verbal agreement ceased on May 29, 2009, pursuant the Company’s execution of a sublease.    

Mark L. Baum, Esq. (“Baum”) our CEO and president, is a managing member of the Noctua Fund Manager, LLC.  James B. Panther, II (“Panther”), Shrink’s chairman of its Board of Directors, is also a managing member of the Noctua Fund Manager, LLC.  As of September 30, 2010, there was $10,750 owed to the Noctua Fund Manager, LLC and $1,750 had been paid to the Noctua Fund Manager, LLC during the nine months ended September 30, 2010.  This liability is recorded as a related party payable on our balance sheets.

The Company subleases space from Business Consulting Group Unlimited, Inc., an entity owned by Panther and Baum, pursuant to which the Company leases approximately 3,000 square feet of office and administrative space, as well as use of, among other things, internet, postage, copy machines, electricity, furniture, fixtures etc. at a rate of $6,000 per month.  The lease with Business Consulting Group Unlimited, Inc. expired April 30, 2010, and has continued as a month to month tenancy thereafter.   For the nine months ended September 30, 2010 $48,000 had been paid to Business Consulting Group Unlimited, Inc and $6,000 was owed to Business Consulting Group Unlimited, Inc.  This liability is recorded as a related party payable on our balance sheets on our balance sheets.

On May 29, 2009, the Company signed an operating agreement (the “Operating Agreement”) with BCGU, LLC, an entity indirectly controlled by Panther and Baum, for a fee of $6,000 per month.  During October 2009, the Company amended the Operating Agreement with BCGU, LLC.  The amended Operating Agreement (“the “Amended Operating Agreement”) allows us to retain certain day-to-day administrative services and management in consideration of a monthly fee of $30,000 per month.  The Amended Operating Agreement also included a $270,000 signature bonus.  The Amended Operating Agreement expires October 1, 2012.  For the nine months ended September 30, 2010 $101,333 had been paid to BCGU, LLC and there was $508,667 owed to BCGU, LLC.  This liability is recorded as a related party payable on our balance sheets on our balance sheets.  There is an option within the Amended Operating Agreement that allows BCGU, LLC to convert outstanding payables related to the Operating Agreement into a 10% convertible note.  At such time BCGU, LLC had not converted any of its outstanding payables into a note.  Because BCGU, LLC is (i) substantially managing the affairs of the company, (ii) familiar with the affairs of the Company and its strategic direction, (iii) receiving minimal cash compensation for its efforts and is sustaining the risk of deferring most payments indefinitely, the Company believes, based on review of its independent directors, that the foregoing transactions and agreements are no less favorable (or even more favorable, given the flexibility) to the Company than would otherwise be readily available from independent third parties.

The Company’s rent expense for the nine months ended September 30, 2010 and 2009 was $54,000 and $36,500, respectively.

The following table represents the Company’s future minimum lease payments for the next 5 years:

2010
$
1,350
2011
 
1,350
2012
 
-
2013
 
-
2014
 
-
Total
$
2,700

 
 
F-8

 

 
NOTE 10.                      CONVERTIBLE DEBENTURES, PRIVATE PLACEMENT OFFERING

We recognize the advantageous value of conversion rights attached to convertible debt. Such rights give the debt holder the ability to convert his debt into common stock at a price per share that is less than the trading price to the public on the day the loan is made to the Company. The beneficial value is calculated as the intrinsic value (the market price of the stock at the commitment date in excess of the conversion rate) of the beneficial conversion feature of debentures.  This feature is recorded as a discount to the related debt and an addition to additional paid in capital. The discount is amortized over the remaining outstanding period of related debt using the interest method.

A.  
Convertible Debentures – Related Party

On May 7, 2009, Shrink Nanotechnologies, Inc. entered into a debt consolidation agreement (the “Debt Consolidation Agreement”) with Noctua Fund LP to consolidate certain secured and unsecured liabilities (“Dao Liabilities”) which were originally assigned to Dao Information Systems, Inc. (“Dao”).  While the Company did make an assignment of the Dao Liabilities to Dao, the Company was legally responsible to Noctua Fund LP for the principal and interest related to the Dao Liabilities.  The principal amount of the secured part of the Dao Liabilities was $76,500 and the principal amount of the unsecured part of the Dao Liabilities was approximately $5,000.  All of the promissory notes underlying the Dao Liabilities have matured and were in default.

The Debt Consolidation Agreement consolidates all monies presently owed to Noctua Fund LP which are consolidated into one new secured convertible promissory note with a principal amount of $100,000.  The note’s maturity date is October 1, 2012.  The new note accrues interest at fourteen percent (14%) but did not begin to accrue interest until October 1, 2009.  Interest payments on the note are due monthly and are in default.  The note has a conversion price of $.04 per share.  The Company determined this to be a substantial modification to the debt instruments and prior to the merger applied debt extinguishment accounting to record a loss on extinguishment of debt of $100,000.

The Company has not made any of the required interest payments and as a result this note was in default and accruing interest at its default rate of 18%.

On May 29, 2009, we assumed convertible notes and accrued interest of $118,121 owed to Noctua Fund LP, as part of the share exchange agreement with the shareholders of Shrink Technologies, Inc. The terms of these notes were then renegotiated into a new note with a principal amount of $118,121.  The note’s maturity date is October 1, 2012.  The note accrues interest at fourteen percent (14%) but did not begin to accrue interest until October 1, 2009.  Interest payments on the note are due monthly.  The note is convertible into shares of our common stock at an original conversion price of $.04 per share.  The Company has determined this to be a substantial modification to the debt instruments and has applied debt extinguishment accounting to record a loss on extinguishment of debt of $118,121 for the year ended December 31, 2009.

The Company has not made any of the required interest payments and as a result this note was in default and accruing interest at its default rate of 18%.

On September 30, 2010, the Company issued a $20,000 14% convertible note to Noctua Fund, LP in exchange of $20,000 cash.  The note’s maturity date is October 1, 2012.  The note accrues interest at fourteen percent (14%), and interest payments on the note are due monthly.  The note is convertible into shares of our common stock at an original conversion price of $.04 per share.  The number of shares issuable upon conversion of the notes shall be determined by dividing the outstanding principal amount, together with accrued but unpaid interest, to be converted by the conversion price. The Company used the effective conversion price based on the proceeds received to compute the intrinsic value of the embedded conversion option.  The Company then calculated an effective conversion price and used that price to measure the intrinsic value of the embedded conversion option.  At the time of the issuance date, the Company recorded a $20,000 discount, which represents the intrinsic value of the beneficial conversion feature.  The discount of $20,000 is being amortized over the life of the note.

Baum, our president and CEO, and Panther, a director, are equal indirect beneficial owners of Noctua Fund Manager, LLC, the general partner of Noctua Fund, L.P., and are non-voting minority investors in the Noctua Fund, L.P.  

B.  
Private Placement Offering

During November of 2009 through early 2010, a confidential private offering (“the Offering”) was made by the Company to various private accredited investors.  The principal amount of the Offering was set at $1,000,000 maximum with excess of $1,000,000 accepted at the option of the Company and consists of convertible notes and stock purchase warrants, with $635,000 of Notes and 3,175,000 warrants issued in aggregate.  The notes will mature at the one year anniversary of their effective date, be sold at their face value, accrue interest at 12% and have a conversion feature that allows the investor to convert the note and accrued interest into common stock at a price of $0.10 per share.  The Company has the option to induce conversion, at which the notes conversion price will be taken at the discounted rate of 80% ($.08 per share).  The Series A common stock purchase warrants are exercisable via cashless exercise commencing six months after each respective closing, at $0.20 per share, beginning to expire 3 years from the first closing of this Offering.  The investors shall be issued warrants to purchase such number of common stock as equals fifty percent (50%) of the number of common shares underlying the convertible note based on the fixed conversion price. The warrants shall contain a standard cashless provision, which permits the holder to exercise the warrants if the stock price is above the exercise price, by turning in warrants and not paying cash.
 
 
 
F-9

 

 
From November 12, 2009 through May 7, 2010, the Company issued  12% convertible notes totaling $635,000 and detachable series A warrants to purchase up 3,175,000 shares of common stock  in exchange of cash as part of the Offering.  The notes’ maturity dates begin on November 12, 2010 through May 7, 2011.  At the time of the issuances, the Company recorded a $444,930 discount, which represents the intrinsic value of the beneficial conversion feature.  The discount is being accreted over 12 month life of the notes.

The Company used the effective conversion price based on the proceeds received to compute the intrinsic value of the embedded conversion option.  The Company allocated the proceeds received from the offering to the convertible instrument and the detachable warrants included in the exchange on a relative fair value basis.  The Company then calculated an effective conversion price and used that price to measure the intrinsic value of the embedded conversion option.  The conversion price of the convertible notes is equal to $0.10 per share of the Company’s common stock.  The number of shares issuable upon conversion of the notes shall be determined by dividing the outstanding principal amount, together with accrued but unpaid interest, to be converted by the conversion price in effect on the conversion date.

Warrants associated with the Offering were issued to purchase up to 3,175,000 shares at an exercise price of $.20 per share.  These warrants are valued at $188,903 and were combined with the beneficial conversion feature of $444,930, to record a total $633,833 discount on the convertible notes.  The warrants are exercisable at 6 months following their effective date and begin to expire 11/12/2012.  The warrants were valued using a Black-Scholes valuation model.  The variables used in this option-pricing model included: (1) discount rates of 1.36-1.64% (2) expected warrant life is the actual remaining life of the warrant as of each period end, (3) expected volatility of 276-300% and (4) zero expected dividends.

There are 1,675,000 and 0 warrants immediately exercisable at September 30, 2010 and 2009, respectively.

Notes Payable consists of the following at:

   
September 30,
 
December 31,
   
2010
 
2009
14% convertible notes due October  2012
$
238,121
$
218,121
12% convertible notes due November  2010
 
100,000
 
100,000
12% convertible notes due January  2011
 
225,000
 
-
12% convertible notes due February  2011
 
110,000
 
-
12% convertible notes due April  2011
 
50,000
 
-
12% convertible notes due May  2011
 
150,000
 
-
Total convertible notes payable
$
873,121
$
318,121
Less: Discount on notes
 
(252,899)
 
(86,389)
Less: Current portion
 
(620,222)
 
(231,732)
Long-term portion
$
-
$
-


The following represents minimum payments due for notes payable:
 
   
Amount
2010
 
318,121
2011
 
535,000
2012
 
20,000
Total
$
873,121

The Company has notes payable due to a related party in the amount of $218,121 with a maturity date of October 1, 2012.  These notes are currently in default due to non-payment of monthly interest accruals and are classified as current liabilities on the balance sheet.   Interest payments are due monthly on these notes.
 
 
 
F-10

 

 
NOTE 11.                   FAIR VALUE MEASUREMENTS

Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.  US GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:
 
 
·
Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
·
Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
·
Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.
 
NOTE 12.                   COMMON STOCK

The Company has made various private issuances of securities to fund its operations and satisfy obligations from time to time.

Following a shareholder action described in a Form 14C filed on with the Securities and Exchange Commission on February 15, 2010, the Board of Directors effected a 5 for 1 forward split.  All per share amounts and calculations in our presentation reflect this change.
 
In March of 2010, we issued 7,250,000 restricted shares valued at $1,232,500 to a consultant in satisfaction of a one year consulting agreement originally entered into in January, 2010 for assistance in developing the Company’s biotech and related products and, in providing research, prototype and product development assistance on our life sciences related products as well instructional videos and materials for use in academic and corporate laboratories.
 
In March of 2010, we issued 8,700,000 restricted shares valued at $1,479,000 to a consultant in satisfaction of a consulting agreement entered into in January of 2010, for public relations, assistance with press releases and branding, marketing awareness programs, procurement of third party research and web/statistical content and investor relations.
 
In March of 2010, we issued 1,500,000 restricted shares valued at $255,000 to a consultant in satisfaction of a consulting agreement entered into in February of 2010, for services relating to marketing of our medical device products, and marketing to researches, academia and medical professionals.
 
In March of 2010, we issued 600,000 restricted shares, subject to restrictions based on continued services over a 3 year period ended March 1, 2013, valued at $102,000 to an accounting professional for previous and ongoing accounting, SEC compliance and financial statement preparation and compilation and related services.
 
In March of 2010, we issued 180,000 restricted shares valued at $30,600 to a consultant in satisfaction of a consulting agreement entered into in March 2010, for services rendered.
 
In March of 2010, we issued 112,500 restricted shares valued at $19,125 to a member of the Scientific Advisory Board, pursuant to an agreement dated as of March 1, 2010.
 
In March of 2010, we issued 40,000 restricted shares valued at $8,800 (in addition to 60,000 shares issued in November 2009) as payment for professional services rendered.
 
In May of 2010, we issued 40,000 restricted shares valued at $8,000 as payment for professional services rendered.
 
In May of 2010, we issued 50,000 restricted shares valued at $10,500 as payment for marketing services related to press releases and branding.
 
In May of 2010, we issued 1,000,000 restricted shares valued at $204,000 to Dr. Sayatani Ghosh, a member of the Scientific Advisory Board (“SAB”) since 2009, pursuant to her SAB agreement dated March 1, 2009.  This agreement has expired by its terms.
 
In July of 2010, we issued 40,000 restricted shares valued at $6,400 as full payment for professional services rendered during the months of June and July.
 
 
 
F-11

 
 
 
In July of 2010, pursuant to an consulting agreement entered into as of June 1, 2010, we issued 76,364 restricted shares valued at $12,000 as payment for solar research and film manufacturing related consulting services rendered during the months of June and July.  The consulting agreement is for a one year term and requires payment of a monthly fee of $6,000 to be paid in shares of common stock of the Company for the duration of the term unless terminated early.
 
In July of 2010, we issued 395,833 restricted shares valued at $92,625 as payment for financial advisory related services, and development of financial models and due diligence research between December 2009 through May of 2010.  In addition, the Consultant was paid cash compensation of $27,708 in 2010.
 
NOTE 13.                   WARRANTS

The following summarizes stock purchase warrants as of September 30, 2010 and December 31, 2009:

       
Weighted Average
   
Amount
 
Exercise Price
Outstanding December 31, 2008
 
-
$
-
Expired/Retired
 
-
 
-
Exercised
 
-
 
-
Issued
 
500,000
 
0.20
Outstanding December 31, 2009
 
500,000
$
0.20
Expired/Retired
 
-
 
-
Exercised
 
-
 
-
Issued
 
2,675,000
 
0.20
Outstanding September 30, 2010
 
3,175,000
$
0.20


The following summarizes the changes in warrants outstanding for the nine months ended September 30, 2010:

 
Warrants Outstanding
 
Warrants Exercisable
 
 
Number
 
Weighted
Remaining
     
Weighted
 
 
of
 
Average
Exercise Life
 
Number
 
Average
Expiration
Date of Grant
Shares
 
Exercise Price
in Years
 
Exercisable
 
Exercise Price
Date
First quarter fiscal 2010
750,000
$
0.20
2.28
 
750,000
$
0.20
1/11/2013
First quarter fiscal 2010
250,000
 
0.20
2.30
 
250,000
 
0.20
1/15/2013
First quarter fiscal 2010
125,000
 
0.20
2.33
 
125,000
 
0.20
1/28/2013
First quarter fiscal 2010
375,000
 
0.20
2.35
 
375,000
 
0.20
2/2/2013
First quarter fiscal 2010
50,000
 
0.20
2.35
 
50,000
 
0.20
2/4/2013
First quarter fiscal 2010
125,000
 
0.20
2.38
 
125,000
 
0.20
2/14/2013
Second quarter fiscal 2010
250,000
 
0.20
2.56
 
-
 
-
4/22/2013
Second quarter fiscal 2010
750,000
 
0.20
2.60
 
-
 
-
5/7/2013
Total at  September 30, 2010
2,675,000
$
0.20
   
1,675,000
$
0.20
 

 
 
 
F-12

 

 
NOTE 14.     STOCK OPTIONS

The Company has issued stock options to consultants, and non-employee's advisors and directors of the Company. These issuances shall be accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, or whichever is more readily determinable. The Company has elected to account for the stock option plan where the compensation to employees should be recognized over the period(s) in which the related services are rendered. The fair value of a stock option granted is estimated using an option-pricing model.

750,000 options were issued to the members of our advisory board.  These options are valued at $260,790 the options are exercisable for 1-3 years following their effective dates that begin to expire 5/29/2011.  During the nine months ended September 30, 2010 the Company recorded a stock option expense of $141,819.  The options were valued using a binomial valuation model.  The variables used in this option-pricing model included: (1) discount rates of 0.53-1.04%, (2) expected option life is the actual remaining life of the options as of each period end, (3) expected volatility of 110%-575% and (4) zero expected dividends.

The following summarizes options as of September 30, 2010 and December 31, 2009:

       
Weighted Average
   
Amount
 
Exercise Price
Outstanding December 31, 2008
 
-
$
-
Expired/Retired
 
-
 
-
Exercised
 
-
 
-
Issued
 
275,000
 
0.22
Outstanding December 31, 2009
 
275,000
$
0.22
Expired/Retired
 
-
 
-
Exercised
 
-
 
-
Issued
 
475,000
 
0.21
Outstanding September 30, 2010
 
750,000
$
0.21


The following summarizes the changes in options outstanding at September 30, 2010:
 
 
Options Outstanding
 
Options Exercisable
 
 
Number
 
Weighted
Remaining
     
Weighted
 
 
of
 
Average
Exercise Life
 
Number
 
Average
Expiration
Date of Grant
Shares
 
Exercise Price
in Years
 
Exercisable
 
Exercise Price
Date
First quarter fiscal 2010
25,000
$
0.11
1.28
 
25,000
$
0.11
1/10/2012
First quarter fiscal 2010
25,000
 
0.20
1.37
 
25,000
 
0.20
2/13/2012
First quarter fiscal 2010
25,000
 
0.23
1.42
 
25,000
 
0.23
3/1/2012
Second quarter fiscal 2010
25,000
 
0.17
1.53
 
25,000
 
0.17
4/10/2012
Second quarter fiscal 2010
250,000
 
0.26
2.55
 
-
 
-
4/17/2013
Second quarter fiscal 2010
25,000
 
0.21
1.62
 
25,000
 
0.21
5/13/2012
Second quarter fiscal 2010
25,000
 
0.15
1.65
 
25,000
 
0.15
5/25/2012
Second quarter fiscal 2010
25,000
 
0.17
1.67
 
25,000
 
0.17
6/1/2012
Third quarter fiscal 2010
25,000
 
0.11
1.78
 
25,000
 
0.11
7/10/2012
Third quarter fiscal 2010
25,000
 
0.08
1.90
 
25,000
 
0.08
8/25/2012
Total at  September 30, 2010
475,000
$
0.21
   
225,000
$
0.16
 

 
 
 
F-13

 

 
NOTE 15.   DISCONTINUED OPERATIONS – AUDIOSTOCKS

During the year ended December 31, 2009, the Company reported a litigation receivable in the amount of $108,011 and accounts payable to former Series C Preferred shareholders for $143,825 related to the disposal of its Audiostocks business segment.  During March of 2010, the Company received proceeds from the litigation settlement to satisfy that receivable and subsequently paid its former Series C Preferred shareholders balance in full.  The Company has disposed of all assets related to its previous business segment, Audiostocks.  The Company no longer has any assets, or liabilities that will be or would be transferred, sold or disposed of related to this business segment.

NOTE 16.   SUBSEQUENT EVENTS

The Company has performed an evaluation of events occurring subsequent to the period end through the issuance date of this report. Based on our evaluation, nothing other than the events described below need to be disclosed.

In October 2010, the Company entered into a lease agreement with the Regents of the University of California.  The lease will commence on November 1, 2010 and will be in force for a minimum of 6 months and a maximum of 24 months thereafter.  Monthly rent payments will be $450.

In November 2010, the Company issued a 12% convertible note and warrants in exchange for $117,000.  The note is convertible at $.10 per share and the warrants are excisable at $.20 per share.  The note matures on November 10, 2012 and the warrants expire on November 10, 2013.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F-14

 
 
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
 
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations has been updated to reflect the restatement of the condensed consolidated statements of operations for the three and nine months ended September 30, 2010 (the “Original Report Date”), the condensed consolidated statement of cash flows for the same period and the consolidated balance sheet as of September 30, 2010. For a more detailed description of the restatement, see Note 2 – Restated Financial Statements. This report, accordingly, speaks as of the Original Report Date and does not update, or intend to update, other Company information or disclosure since such time.  This entire amended Report, and this Management Discussion and Analysis of Financial Condition and Results of Operations, accordingly, does not contain current information about the Company and should only be viewed or considered in conjunction with the more recent reports and information filed by the Company from time to time after the Original Report Date.
 
The following discussion and analysis should be read in conjunction with our unaudited financial statements and related notes included in this Report and the “Forward Looking Statements” section in the forepart of this Report (see page ii above) and the “Risk Factors” set forth in Part II of this Report, as may be amended or updated from time to time.  The statements contained in this Report that are not historic in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “expects,” “anticipates,” “estimates,” “believes,” or “plans” or comparable terminology are forward-looking statements based on current expectations and assumptions.  These statements are based on current information available to management at the time of the Original Report Date and does not reflect the more recent material changes to the Company since such time, as reflected in our Annual Report on Form 10K for the period ended December 31, 2010, and other more recent reports, except as otherwise specifically noted herein.   No assurance can be made that any of our forward looking statements will materialize as planned.
 
Various risks and uncertainties could cause actual results to differ materially from those expressed in forward-looking statements. Factors that could cause actual results to differ from expectations include, but are not limited to, those set forth under the sections “Forward Looking Statements” above, and “Risk Factors” and other business risks and information, set forth herein.
 
For ease of reference we use certain defined terms as defined in “Use of Terms” on page iii above, in the forepart of this Report.
 
Background

General

We are a research, design and development company dedicated to the commercialization of a nanotechnology platform called the ShrinkChip Manufacturing Solution™, which we believe represents a new low cost paradigm for fabrication of otherwise costly diagnostic chips and various other nano-size structures and devices with a multitude of applications.  Our manufacturing technology can be used to manufacture plastic (or polymer-based) chips and other devices used as measuring tools and energy and content transfer devices for a wide range of applications from the life sciences, drug and chemical analysis industries to the optoelectronics components, printed electronics and solar/renewable energy businesses.
 
 
Our technologies, in certain applications, also avoid high manufacturing costs such as specialized facilities with clean rooms and expensive, high tech manufacturing apparatus.

Many of the applications we seek to commercialize are being developed for markets that have entrenched products and technologies which serve the needs of the users that purchase for these markets.  We seek to offer a new approach and hopefully one which offers lower cost, more flexibility and produces equal or better results for the user/consumer.
 
Assets; Intellectual Property and Research Agreements
 
Our assets include exclusive and non-exclusive patent rights, as more fully described in this report, from four main agreements, as follows:
 
·  
Our Research Agreement entered into with UC Merced allowing us to exclusively license technologies developed through our funding,
 
·  
Our Existing License Agreement, entered into in April of 2009, with the UC Regents, granting us an exclusive license (with certain exceptions) to microfluidic fabrication and other inventions (the “License Agreement”),
 
·  
Our two Sponsored Research Agreements with the UC Regents on behalf of University of California, Irvine campus entered into in May 2010 (the “Biosensing Research Agreement”), and in September 2010 (the “EB Research Agreement”), and rights to acquire additional license rights funded by us under these agreements, (the “Sponsored Research Agreements”),
 
·  
Our exclusive Patent and Know-How License Agreement (the “Corning License Agreement”) with Corning Incorporated (“Corning”) wherein the Company licensed the exclusive worldwide right to use and sublicense Corning’s patent-pending Modular Microfluidic System and Method for Building Modular Microfluidic System.
 
 
 
Page 1

 
 
 
We also entered into other agreements, such as the one with the MF3 Consortium, accessing matching funds from MF3’s relationship with DARPA™, that provide us with research co-funding agreements as more fully provided below. Finally, we intend to commercialize our assets through relationships with third party manufacturers we contract with.  No assurance can be made that the Company will have funds sufficient to further develop and license new technologies or to commercialize the ones we have.
 
FIGA™ Business

Due to limited cash resources, and to capitalize on government and institutional grants and our management’s relationships with universities, we have fashioned our business using a corporate development model called FIGA™ which is an acronym that stands for: Finance, Industry, Government and Regulatory and Academia.  Under this model, we have sought to access experts in the market segments we seek to impact – by building an “expert network” comprised of people with backgrounds in specialized areas of finance, industry, government and regulatory affairs and academia.  We believe that as a small business with limited resources, attracting experts from these areas and using them as key drivers for how we allocate our resources will allow us to add more value quicker for our shareholders.  This model also involves the use of exploring grant availability and programs where able.

Business Strategy

Our core shrink-film technology, branded as “NanoShrink™,” is a “platform technology” with a variety of applications in numerous fields that relate to the use of and functionalization of nano-sized structures, including channels, tubes, holes, wrinkles as well as “cracked” surfaces.  These technologies have a number of applications (many mentioned herein) in a wide variety of industries, including without limitation, the life sciences/diagnostic test industries to solar and optics applications.

We acquired our assets and rights by using a business model that has inexpensively allowed us to license technologies from two primary sources: (1) university laboratories, and (2) “secondary” technologies from very large industrial businesses.  Traditionally and historically, university engineering labs have been used as commercial resources for venture capital organizations and other funding sources looking for high quality low cost technology.  However, as a result of a number of negative economic factors over the past few years limiting private sector access to these funds, Shrink has been able to strategically locate select engineering – primarily in the biomechanical engineering space – and develop sponsored research arrangements that fund critical research and also provide us with access to intellectual property with commercial potential.

We have also recently undertaken a program to develop commercial relationships with larger, multi-national United States-based industrial companies in order to potentially work with their technologies and products which have been abandoned or “orphaned” for one or a number of reasons – primarily due to a limited market opportunity or limited funding at the time of abandonment.  We are actively seeking to develop licensing agreements in this regard to provide the right to develop and market these “orphaned” technologies and product lines.

We presently have the right to exclusively license (with the exception of certain rights reserved by universities for educational purposes) a number of technologies (as well as future technologies developed through additional university-specific agreements), pursuant to agreements we have with the Regents of the University of California (or, the UC Regents), as described more fully herein and in our previous public company SEC reports and press releases.  Some of these rights stem from research we sponsored or have agreed to sponsor.

In addition to our licensed technologies, we may develop technologies on our own as a result of our research or joint development activities.

We also have developed a Science Advisory Board (“SAB”) and a Product Development and Commercialization Committee (“PDACC”) to the Company.  Through the relationships with our SAB members, we have the exclusive right to certain intellectual property rights derived from their respective work for the Company.  To date, we have not filed any applications to protect intellectual property rights derived from work provided to the Company by a member of the SAB or the PDACC.

We are focusing on developing and commercializing our technologies in three specific business segments which are discussed in greater depth in this Report: (1) our NanoShrink™ business, (2) our StemDisc™ business and (3) our renewable energy generation and transmission business.  As we develop additional uses for our core “Shrink Film” abilities (discussed below), we will likely add to the market segments we seek to enter.  All of the business segments we presently are engaged in are relatively immature and require additional development before products may ultimately reach a commercial customer.  The Company has made material business developments and changes since the Original Report Date of this Report, as disclosed in its more recent annual and other reports, all of which should be  considered by readers.

We also intend to review, and as such opportunities present themselves, seek to acquire synergistic assets and businesses, although these are not within the Company’s primary initial focus as management believes that initial development, manafucturing and commercialization will be most economical through joint venture or third party OEM manufacturers we contract.
 
 
 
Page 2

 

 
Core “Shrink Film” Abilities

Our core technologies allow for the flexible and rapid design, prototyping and manufacture of certain complex chips, polymer-based nano-structured systems and microfluidic diagnostic tools and measuring devices.  Our low cost manufacturing processes and materials avoid costly expenditures such as factories with clean-rooms and complex machinery.  This is made possible by our ability to design at a larger scale and then use the inherent properties of our NanoShrink™ plastic material to functionalize a device by controllably shrinking the same by a factor of up to 95%, through a proprietary process.  While the markets for what we can do is meaningful, we believe that our “shrinkable technology” offers, a low cost and flexible replacement for existing chips and related devices which are currently being manufactured through very expensive and relatively inflexible manufacturing processes primarily using soft lithograph, a technology that was developed from the semi-conductor industry.

These kinds of devices are most actively used in the life sciences industry and for diagnostic purposes. However, some of our products, we believe, have viable applications in the alternative energy generation and information and energy transmission industries.

Technology and Intellectual Property

We license or have the right to license, through various agreements mentioned above with the University of California, Merced (“UC Merced”) and the UC Regents, various patent applications and rights relating to the ShrinkChip Manufacturing Solution™.  A description of these agreements and related technologies, applications and cost estimates is provided herein and in our Reports, along with a list of patents and other intellectual property owned by, or licensed to us.  More recently, as of July 2010, we have licensed a fully functional “plug and play” modular microfluidic system and method from Corning under the Corning License Agreement (i.e. the “Corning License”).  Our agreements provide us with certain rights to the filed patent applications with the US Patent and Trademark Office (“USPTO”) and we possess significant know-how as it relates to using shrinkable films in the manner in which we seek to design and build products for our focused markets.

Our sponsored Biosensing Research Agreement with the UC Regents on behalf of the Irvine, California campus, was entered into as of May 3, 2010.  Under this sponsorship agreement we agreed to fund various specified research projects and, in the event viable inventions or discoveries are made, we have the right to exclusively (with exception for educational or similar purposes) license those fees in exchange for up front and royalty fees.  We have negotiated this agreement to grant us (presuming no default) the exclusive access to license inventions which have been developed by this laboratory as early as July 1, 2009.

Review of and Abandonment of Intellectual Property Rights

We may, from time-to-time and as a result of rights granted in one or more of our (or our subsidiary’s)  licensing agreements, take a license to inventions (and the related license to domestic and international patent application rights) which result from a sponsored research arrangement or private (non-academic sector) license agreement.  Doing so may trigger the license to Shrink, but will also trigger the payment of certain fees and various ongoing financial commitments, all of which have been negotiated and are disclosed in the license agreement.

The Company regularly reviews its licenses and patents and, as technologies or inventions have been further commercially vetted or newer competing technologies are developed by others, management may determine using its reasonable business judgment, to not continue to support the development of a technology, and may therefore abandon its licensing rights and or intellectual property rights (if not otherwise licensed) with respect to that technology, invention and the related license.  The Company may abandon intellectual property rights which it formerly thought would be valuable or which may still have some value but would be too expensive to maintain.  These same abandoned intellectual property rights may have been a part of a public announcement and even been a key part of the Company’s operational strategy.

Abandonment or an outright termination of a license to a particular invention may occur more often as Shrink acquires more IP rights, and the same inventions are commercially vetted.  License or patent rights may also be abandoned based on no other reason other than limited capital or the Company’s need to expend its capital on other vital needs.  To the extent the Company abandons such non-critical intellectual property rights, the Company may not file a specific abandonment notice.  With respect to the UC Regents, the Company remains obligated, for 90 days after abandonment, to pay for various costs related to abandoned intellectual property, including attorneys’ fees and maintenance costs.


During the fourth quarter of 2010, we, with our Scientific Advisory Board, intend to review the viability of our intellectual property licensure relationship with the UC Regents.
 
Corporate History and Structure
 
General.

We were incorporated in the state of Delaware on January 15, 2002 as Jupiter Processing, Inc.  On January 13, 2005, the Company changed its name to Audiostocks, Inc., which was again changed on May 14, 2009 to Shrink Nanotechnologies, Inc. in anticipation of its acquisition of Shrink Technologies, Inc.  On May 29, 2009, the Company entered into and completed a share exchange agreement with the former principal of Shrink Technologies, Inc., for the acquisition of Shrink which held and continues to hold, most of our related business assets and has agreements with both UC Merced and the UC Regents granting the Company the exclusive rights to the Shrink related technologies discussed herein.  Since this time we also entered into, among other things, our Corning License Agreement and the MF3 Consortium Agreement.  We have two additional, recently organized, business-specific operating entities: Shrink Solar, LLC and Shrink Chips, LLC.  All subsidiary entities to Shrink Nanotechnologies, Inc. are 100% owned.  Below is a chart of our present corporate structure:   
 
 
 
Page 3

 
 

 
 
We have extremely limited cash on hand, limited liquidity in our publicly traded common stock, and our funds are allocated towards research, development and commercialization of our technologies and products, identifying and retaining executive management that will be able to clear the Company’s path into the life sciences industry.

We have disposed of our Audiostocks related operations and assets.   Nonetheless, certain information relating to our previous AudioStocks business is contained towards the end of this “Business” section below, but should not be relied upon as meaningful in assessing our Shrink operations.

Our common stock was quoted on the Over-the-Counter Bulletin Board under the symbol “INKN” through Tuesday, April 13, 2010.  On April 15, 2010, and as a result of our Forward Split which became effective, the Company’s common stock trading symbol was changed to “INKND.”  Effective as of May 14, 2010, the symbol for our common stock was changed back to INKN.  All references to share amounts, exercise, sale or conversion prices in this Report are as adjusted to reflect post forward split amounts and prices.

Our principal offices are located at 2038 Corte Del Nogal, Suite 110, Carlsbad, California, 92011.  Our phone no. is 760-804-8844, and our main contact person is Mark L. Baum, Esq., our CEO.  Our main corporate website is www.shrinknano.com.
 
Shrink As Accounting Acquirer

As a result of our Shrink Acquisition from Shrink’s former shareholder Mr. Marshall Khine, we have succeeded to the business and research and development operations of Shrink, which now constitute our primary asset and operations.  Accordingly, Shrink is deemed the financial acquirer for accounting related purposes and, the financial statements presented in Part I of this Report, and in this Management Discussion and Analysis of Financial Condition and Results of Operations, are those of Shrink, unless the context requires otherwise. At such time, we were in the process of disposing of our AudioStocks related business.

Summary of Shrink Acquisition Terms

We acquired 100% ownership of Shrink from its sole shareholder, Marshall Khine in May 2009 in exchange for one third of the Company.  We have since formed two additional subsidiaries focused on solar and chip disciplines (see previous chart).  Shrink’s (and therefore the Company’s) primary assets is a license agreement with the the UC Regents granting Shrink intellectual property rights in patent rights owned by the UC Regents and the rights under the license agreement with UC Merced.  In addition Shrink owns certain trademarks and other intellectual property.

As consideration for the acquisition of Shrink, the Company issued an aggregate of 44,444,440 shares of its common stock (approximately 1/3 of the Company) and 50 shares of its Series C Preferred Stock, which preferred stock has since been cancelled.  In addition, the Company (i) assumed pursuant to the terms of a note exchange agreement, the outstanding notes due to Noctua Fund LP, which had an aggregate outstanding balance (at the time) of approximately $118,121, (ii) agreed to issue 495,500 shares of common stock to the UC Regents as the initial consideration under Shrink’s license agreement with it (iii) provided the seller with one seat on the Company’s Board of Directors which went to Mr. Marshall Khine, Esq., and (iv) agreed to comply with all outstanding commitments made by Shrink and its consultants, including members of Shrink’s Scientific Advisory Board and its Business Advisory Board.  Additional information relating the Shrink Acquisition and Shrink itself is contained in our Current Report on Form 8-K, Filed on June 5, 2009, and exhibits thereto the provisions of which are incorporated herein.
 
 

 
 
Page 4

 
 
 
Plans for Preexisting Operations

Prior to and since the Shrink Acquisition we were operating and looking to liquidate, our investor relations and other internet businesses.  Throughout 2009, the Company successfully and completely initiated transactions and agreements to dispose of its investor relations and related internet business (i.e. the AudioStocks business) software in its entirety and do not intend to continue operations in that operating segment any longer.  Any revenues, expenses, assets or liabilities of the Audiostocks business presented in our financial statements, currently and historically, have been disclosed or restated as discontinued operations.

Nonetheless, certain software and aspects of our remaining pre-existing business related to our search engine platform (“Stockvert”) have been and will be relied upon for certain internal accounting functions and may be monetized, either through sale or license, to 3rd parties in the future.  The sale and/or license of this software is not being actively pursued by management at this time.  Aspects of the Stockvert business segment do not meet all of the requirements to be reported in discontinued operations.  In particular, the Company’s use of the accounting functions derived from the Stockvert business that have been uniquely customized, and therefore operationally valuable, will not be eliminated from our ongoing operations.
 
Because we were operational and have revenues from non Shrink related operations in previous periods prior to the Shrink Acquisition, certain portions of this Report and specifically, this Management Discussion and Analysis of Financial Condition and Results of Operations, also contains information that may relate to our previous, non-Shrink related operations, which are no longer material to our business.  As our operations switched to those of Shrink as of May 29, 2009 with Shrink as the surviving accounting acquirer, and since Shrink is a development stage company, a comparison for our pre-Shrink Acquisition business revenues and operations with those of Shrink’s would not necessarily be appropriate or meaningful in this Report.  Moreover, as Shrink on its own has limited operations or history, there is little historic information upon which shareholders may assess our business prospects.
 
 
Recent Patent Developments.

We obtained patent pending status relating to our StemDisc™ technologies and for its rapid prototyping system for the manufacture of its LOC devices.  These patents are owned by the UC Regents and licensed to the Company pursuant to the Company’s existing License Agreement with them.

A list of the recently filed patents, patent filing numbers and applications is as follows:

Patent Name
Patent Pending No.
Description
Honeycomb Shrink Wells for
Stem Cells Culture
US 61/161,338 and
US 61/177,871
Tunable shrink-induced honeycomb microwell arrays for uniform embryoid bodies
     
Process for Rapid Microfabrication Using Thermoplastics and Devices
US 61/003,113 and
US 61/018,881
Low cost biochip prototyping station which provides for rapid design, fabrication and manufacture of customizable biological research chips

We are required by our license agreement with the California Regents, to pay the costs of obtaining patents.  The Company regularly reassesses the technologies and applications we have, develop, or acquire an interest in, so as to determine, in good faith, whether the benefits of obtaining a patent outweigh the costs of obtaining it and the resulting public disclosure of our processes, technologies or proprietary technologies.   The Company regularly revisits its patent prosecution and maintenance policies based on its budget constraints and business goals.

No assurance can be made that the Company will be able to assess the patent-worthiness of all its products, or, if a patent is desirable, that the Company will have sufficient funds or wherewithal to secure or prosecute its intellectual property rights.

During the 4th calendar quarter of 2010, the Company intends to evaluate the commercial viability of its intellectual property rights licenses that are owned by the UC Regents.  Results of the assessment could include maintaining the status quo, terminating the Company’s rights to selective rights or attempting to renegotiate its relationship with the UC Regents.
 
 
 
Page 5

 

 
Certain Foreign Patent Applications Abandoned and Waived

We regularly review the cost-benefit analysis of our various patent applications, and, depending on costs, capital on hand, and other resources necessary, management may abandon one or more patent applications in one or more jurisdictions, and/or, may apply for or prosecute similar or different patents in different jurisdictions.  Management determined, based on limited need and substantial application and prosecution costs, to waive and abandon Shrink’s rights to several patents pending.  No assurance can be made that the Company will have sufficient funds to patent or protect all of its needed intellectual property or that abandoned patents will not one day be needed.

We also converted a provisional international patent application, for Aligning Cells on Wrinkled Surface (Filed August 26, 2009) to a completed patent pursuant to 35 U.S.C. Sec. 111(a).

Management also determined that the costs in converting certain provisional patent applications to complete applications in the US and internationally outweighed the benefits to the Company in pursuing the same at this time given the Company’s limited resources and limited use for these patents at this time. These abandoned applications include patent applications for our Quantum Dot Solar Concentrator™, filed in October 2009; our Process for Fabrication of Nanoholes, Related Structures, and Devices Thereof, filed in October, 2009; our Quantum Dot Solar Concentrator, filed August 2009; our High Surface Area Micro and Nanobeads, filed September of 2009; and our High Resolution Light Emitting Devices, filed August 27, 2009. As management believes that commercializing these patent uses is not viable at this time, and since the Company intends to focus its resources on maintaining its core technology patents, management determined that the added extensive costs and resources in maintaining these patent rights outweighed the benefits to the Company.  Despite abandonment of certain patents, we remain responsible for certain patent prosecution costs for 90 days after abandonment.

Management regularly revisits its patent application and prosecution process and may re-elect to protect these rights (or others) or allow others to lapse from time to time, depending on whether our needs necessitate the same and subject further to available funding and technology resources.  No assurance can be made that we will not need these abandoned rights in the future or, that if needed, that we will be able to re-assert our specific rights or protections.

Proceeds of Debt Financing

Private Placement of 12% Convertible Notes and Series B Warrants

During November 2010, the Company issued, $117,000 in 12% convertible notes initially convertible (post forward split) at $.10 per share, and 585,000 Series B Common Stock Purchase Warrants, exercisable at $0.20 per share (or, “Series B Warrants”) as part of the offering  for a cash purchase price of  $117,000. The Notes and Series B Warrants were sold at face value for each dollar amount of Notes sold.  No placement agent compensation has been paid in this financing.

The foregoing are the material terms of the 12% note and Series B Warrant financing.

2009 Private Placement of 12% Convertible Notes and Series A Warrants;

Between November 2009 through May, 2010, the Company issued, on a private basis, $635,000 (inclusive of $100,000  reported in our Annual Report on Form 10-K, as previously filed) of 12% convertible notes initially convertible (post forward split) at $.10 per share, and 2,675,000 Series A Common Stock Purchase Warrants, exercisable at $0.20 per share (or, “Series A Warrants”) as part of a  private financing at face value for a purchase price of  $535,000. The notes are repayable one year from issuance (with some of the earliest issued notes becoming due in November 2010) and the warrants are exercisable commencing 6 months from issuance and expire 36 months from issuance.   At any time following its maturity date, the Company may induce conversion of the notes at a discounted rate at 80% of the effective conversion price.

When combined with notes and warrants sold during late fiscal 2009 (and not including any 14% convertible notes issued to Noctua Fund, L.P.) the following is a brief summary of the notes and warrants outstanding:
 
·  
$635,000 principal amount 12% convertible notes, currently convertible at $.10 per share into an aggregate of 6,350,000 shares of common stock (plus shares issuable as interest), payable one year from their respective issuance dates, and
 
·  
3,175,000 Series A Warrants, exercisable at $.20 per share, and expiring three years from their respective issuance dates.
 
The foregoing are the material terms of the 12% note and Series A Warrant financing.  Other details of the same may be found below in this Report and in our Annual Report.
 
 
 
Page 6

 

 
Sponsored Research Agreements with UCI

Sponsored Research Agreement with UC Regents (September 2010)

As of September 22, 2010, Shrink entered into the Sponsor Research Agreement (or, the “EB Research Agreement”) with UC Regents on behalf of the Irvine Campus (“UCI”).  The EB Research Agreement was for a term of three months, retroactively beginning August 1, through October 31, 2010.  The EB Research Agreement may be terminated by the Company or UCI subject to satisfying the appropriate notice requirements required under the agreement.

The EB Research Agreement provided, among other things, that the Company sponsor specified research relating to the development of a complete system for culturing, imaging, and digitizing a large number of embryoid bodies (EBs) in custom-designed microfluidic devices, including developing protocols for staining and imaging EBs in 3-D.  In addition, the research will also involve specifying and testing a suitable hardware/software platform for collecting images in a high-throughput setting.    Regarding any inventions, discoveries or other commercially useful research products that may arise from research being conducted under the SRA, we will have a time-limited, first right to negotiate an exclusive license of such things with UCI.

The Company’s research sponsorship obligations require it to provide funding (which may be from the Company or other third parties) totaling up to $67,040 during the three month term of the EB Research Agreement.

No assurance can be made that the Company will attain the funding necessary to fulfill its funding obligations under the SRA or, that the research performed will necessarily produce commercially viable new inventions.  In addition, in the event that discoveries are made, no assurance can be made that the Company will be able to fund commercialization of these technologies or that it will exercise its right to an exclusive license of these products.

Sponsored Research Agreement with UC Regents (May 2010)

As of May 3, 2010, Shrink Parent entered into the Sponsored Research Agreement (or, the “Biosensing Research Agreement”) with UC Regents on behalf of UCI.  The Biosensing Research Agreement is for a term of three years or such time as the research is completed, whichever is longer. The Biosensing Research Agreement may be terminated by the Company subject to satisfying appropriate notice requirements required under the agreement.

The Biosensing Research Agreement provides, among other things, that the Company will sponsor specified research relating to development of (i) integrated, manufacturable, nanostructured substrates for biosensing and testing of new bioassays as well as assessing viability of other shrinkable materials, and (ii) stem cell tools that use shrinkable plastic microfluidic technologies, each as more fully provided in the Biosensing Research Agreement.  The Biosensing Research Agreement provides that the Company shall sponsor the research costs up to a budget of $632,051, of which $20,000 has been paid to the UC Regents.  We have exclusive access to license intellectual property from the Biosensing Research Agreement beginning from July 1, 2009 forward according to the terms of the Biosensing Research Agreement.

The Company’s research sponsorship obligations require it to provide funding (which may be from the Company or other third parties) totaling $632,051 during the three year term of the Biosensing Research Agreement.  Of this amount $202,796 is to be paid during the 12 month period ended April 30, 2011; $211,311 shall be paid during the 12 month period ended April 30, 2012; and the remaining $217,944 shall be paid during the 12 month period ended April 30, 2013.  The foregoing payments are to be paid in quarterly installments of ¼ of the total cash fees payable during such 12 month period.

No assurance can be made that the Company will attain the funding necessary to fulfill its funding obligations under the SRA Agreement or, that the research performed will necessarily produce commercially viable new inventions.  In addition, in the event that discoveries are made, no assurance can be made that the Company will be able to fund commercialization of these technologies or that it will exercise its right to an exclusive license of these products.

Matching funds from DARPA Co-Funding Agreement

The Company has become party to a Consortium Agreement (or, the “DARPA Co-Funding Agreement”) among Academic Partners and Sponsors of the Micro/Nano Fluidics Fundamentals Focus MF3 Center, which is headquartered at the University of California, Irvine campus, which provides for partial “matched” funding from the Defense Advanced Research Projects Agency (or, “DARPA”).  The DARPA Co-Funding Agreement becomes effective as of June 1, 2010.  The terms of the DARPA Co-Funding Agreement provides, among other things, that DARPA will match the Company, dollar for dollar (i.e. will provide 50% of certain funding on a “matched” dollar for dollar basis with third parties, if any), for funding commitments made by the Company, through a sponsored research agreement that is otherwise eligible for DARPA marching funds.  We have not received any capital commitments for fundings yet and no assurance can be made that we will make or secure additional financing for research projects that qualify for DARPA matching funds, or that we will remain eligible for the same.

The foregoing are the material terms of the SRA Agreement and the DARPA Co-Funding Agreement, which are both  subject to risks and uncertainties, a copy of which were filed as an exhibit to this report as incorporated from our Current Report on Form 8-K, filed May 7, 2010.
 
 
 
Page 7

 
 
 
Additional New Shrink Nanotechnologies Developments

Below is additional content related to public announcements the Company has made From June of 2010 to the present date:

·  
We formed a new subsidiary called ShrinkChips.  We did this in order to segment and hopefully attract financing for our cell culturing devices business.  We believe that we have created what may become a platform for the development of a number of products in the cell culturing space, and we wished to segregate the affairs of this business from those of, for example, our printed electronics efforts.  We believe the first of the products in the cell culturing segment of our business will be available for commercial sale in the latter part of 2010 or early 2011.
 
·  
We have created a suite of “tools” for our NanoShrink™ plastic design material business.  These tools will be used in order to maximize the performance of the NanoShrink™ material.  The Company intends to eventually offer these tools for sale as a part of a science kit, which may eventually be marketed to schools in the US and abroad.
 
·  
We filed (as inventors, along with the UC Regents) a new patent for Cell Align, a tissue engineering platform which has been shown as an effective substrate for the growth of a number of tissues which require a “scaffold” – such as cardiac tissue as one example.  We intend to continue to file intellectual property in this space and we believe that what we have is an important product for biologists and drug developers.  We count Cell Align as part of the ShrinkChips product offerings we intend to development and market in the near future.
 
·  
We announced that we will open an office in the UC Irvine Tech Portal in November of 2010.  This office will assist the Company is the manufacture of certain components for our products and additional critical affairs of, in particular, the Shrink Chips subsidiary, will be conducted at this office.
 
·  
Dr. Michelle Khine, our scientific founder was awarded a $2.295M grant from the National Institutes of Health enabling her to continue to work on low cost diagnostic devices which are based on the use of shrinkable plastic film, including the Company’s NanoShrink™ material.  The company believes that as long as NanoShrink™_ is a part of the basis for Dr. Khine’s work, that Dr. Khine will be a customer for NanoShrink™ and a developer who will publish on the various uses for the NanoShrink material.  This could assist the Company as we seek market acceptance for our platform in the company year (2011).
 
·  
We recently announced acquiring worldwide exclusive rights to a Corning, Inc.-owned modular microfluidic system technology, which is patent-pending.  The technology  allows for an individual to custom build microfluidic devices and systems and has a number of accompanying technologies (pumps, valves and others) in order to make the system work.  We intend to seek partnerships with potential manufacturers of the components and to offer a kit for sale to users of these systems.  The company does not believe that such systems will be offered for sale during the next 12 months as continued research and development will be required in order to offer such a kit for sale.
 
Critical Accounting Estimates

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The significant accounting policies that are believed to be the most critical to fully understanding and evaluating the reported financial results include revenue recognition, recoverability of intangible assets and the recovery of deferred income tax assets.

Our intangible assets consist principally of intellectual properties such as licensing rights and patents. We are currently amortizing certain intangible assets using the straight line method based on an estimated legal life, of fifteen years.  We began amortization of the NanoShrink™ related patents in June of 2008 since patent filings were first being filed.  The Company will re-evaluate its amortization practice once products related to these patents are put into full production.  When our products are placed in full production we can better evaluate market demand for our technology.

We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or indicate that impairment exists. Once our intellectual property is placed into productive service, we expect to utilize a net present value of future cash flows analysis to calculate carrying value after an impairment determination. 

As part of the process of preparing our financial statements, we must estimate our actual current tax liabilities together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheet. We must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not likely, a valuation allowance must be established. To the extent we establish a valuation allowance or increase or decrease this allowance in a period, the impact will be included in the tax provision in the statement of operations.

Nine Months Ended September 30, 2010Compared to the Nine months ended September 30, 2009 and the Three months ended September 30, 2010 compared to the Three months ended September 30, 2009

Results of Operations; Material Changes in Financial Condition

The most significant events and changes to our Company’s corporate structure during the nine months ended September 30, 2010, were the implementation of the 5-for-1 forward stock split, the sale of $535,000 of Notes and Series A Warrants and entry into various agreements with service providers in exchange for stock compensation aggregating 19,472,500 shares issued during such period.  During this period, the Company also secured certain additional patent pending applications and retained experienced scientific advisors for our advisory board.
 
 
 
Page 8

 

 
During the nine months ended September 30, 2009, the Company (i.e. Shrink Parent), prior to its acquisition of Shrink, had implemented part of its capitalization restructuring and was still operating portions of our StockVert business as more fully detailed herein to the extent material.

Our Shrink subsidiary is and was, prior to our acquisition, a research and development company only and did not and does not, have revenues.

As Shrink is a development stage company, in the health sciences technology industry, we expect to incur substantial additional investment expenses in (i) supporting our research obligations, which involves, among other things, further research and development, and funding license agreement costs, (ii) commercializing our Shrink related technologies.

Since our acquisition of Shrink we have also made various trademark applications relating to our SHRINKCHIP™ and other technologies and entered into additional service or research contracts to develop our manufacturing process.  We have also exercised our rights under our first license with the UC Regents and have funded the patent filings thereunder.

During the nine months ended September 30, 2010, we expended approximately $165,918 towards research and development, of which $32,777 was expended through the three months ended September 30, 2010.

Revenues

Our Shrink business is a development stage company that has not commercialized its technologies yet, Shrink has not had revenues and, we do not expect to have revenues from Shrink’s operations until at least 2011.   We have disposed of most of our non-Shrink related business, other than StockVert which has not had revenues in 2010 or 2009.

Operating Expenses

We had total operating expenses of $3,686,796 related to our Shrink operating activities for the nine months ended September 30, 2010, as compared to operating expenses of $999,511 for the same period of 2009.  For the three months ended September 30, 2010 we had $1,089,427 total operating expenses, as compared to operating expenses of $601,042 incurred during the three months ended September 30, 2009.

We expect operating expenses to continue as we invest further in research and development activities.  We do not have capital commitments yet to cover any of our operating expenses and to date.  To date, our capital needs for Shrink have been funded by grants, restricted stock issuances and private convertible debt financing.

We have limited cash on hand, and to the extent we are able to negotiate with parties with whom we enter into business agreements with to accept stock in lieu of cash, these issuance could dilute the ownership of our shareholders.

Net Loss From Operations

For the nine months ended September 30, 2010, we had a net loss of $4,150,264 from operations as compared to a net loss of $1,031,147 from operations for the period ended September 30, 2009.   For the three months ended September 30, 2010 we had a net loss of $1,276,138, as compared to a net loss of $618,592 during three months ended September 30, 2009.   Management attributes the increase in net loss to, an increase in operational and research activities relating to our Shrink business and, more recently to our funding efforts for Shrink.

We anticipate continued losses relating to investment into our research and development activities relating to Shrink, and to our capital raising activities.  We intend to fund our R&D activities, as we have in the past, through government grants, partnerships and arrangements with universities (such as those that are in effect with the University of California Regents) and equity and debt financings.
 
Discontinued Operations – Audiostocks Business Division
 
In 2008 and 2009, we continued to operate our AudioStocks business while selling off its assets and winding it down through November of 2009.

We anticipate that further gains and losses relating to previous non-Shrink related businesses will diminish as we have wound down or sold these related operations in between late 2008 and 2009.  We do not currently incur material expenses related to these businesses.
 
 
 
Page 9

 

 
Because we no longer operate in this segment, management believes that extensive disclosure on this business is not material to an understanding of our Shrink business.  In addition, a comparison of our new research and development activities to our previous internet and investor relations business would not be meaningful to investors. Accordingly, the focus of this Report is on our Shrink related research and development business and business plans and the previous Shrink business, which is deemed the accounting acquirer after the Shrink Acquisition in May 2009.

Liquidity and Capital Resources

Our cash on hand at September 30, 2010 was $2,932 as compared to $81,978 on hand on September 30, 2009.  The decrease as compared to last year is primarily attributable to our recent lack of financing activities.  Between May and September of 2010 we have not been actively pursuing any specific financing, but the Company does intend to raise capital, if able, to continue its operations as needed.

Given our current commitments and working capital, we cannot support our operations for the next 12 months without additional capital (See “Need for Additional Capital” below and “Risk Factors” section below).

In early May, 2010, through our entry into a Consortium Agreement with Micro/Nano Fluidics Fundamentals Focus MF3 Center, as led by the University of California at Irvine,  our research qualified to receive matched funding from Defense Advanced Research Projects Agency (or, “DARPA”), as described above.   Under the policies of the consortium agreement the Company’s funded research projects are eligible to receive matched funding on a dollar-for-dollar basis, for each dollar we invest in certain qualifying projects.   Since we are dependent on our ability to raise additional capital for our research, no assurance can be made that we will be able to utilize this funding source.   Even if we do raise additional capital, no assurance can be made that we will dedicate it towards those same research projects that qualify for DARPA matching funds.

Our expectations are based on certain assumptions concerning the anticipated costs associated with any new projects.  These assumptions concern future events and circumstances that our officers believe to be significant to our operations and upon which our working capital requirements will depend.  Some assumptions will invariably not materialize and some unanticipated events and circumstances occurring subsequent to the date of this Report.  A portion of our research is being conducted by the University of California, through grants.  We will continue to seek to fund our capital requirements over the next 12 to 24 months from the additional sale of our securities; however, it is possible that we will be unable to obtain sufficient additional capital through the sale of our securities as needed.

As part of the Company’s business plan and when feasible, it regularly elects to pay consulting and professional fees in stock, as opposed to cash, so as to preserve capital.   In particular, between April and July 2010, the Company issued an aggregate of 1,602,197 shares of restricted common stock to five consultants and professional service providers for services rendered, some of which covers services rendered through mid 2010.  The Company recognizes, however, that share issuances are highly dilutive to investors and existing shareholders and, not all service providers are willing to accept share compensation in lieu of cash.  Accordingly, the Company is required to expend funds regularly for services.

The amount and timing of our future capital requirements will depend upon many factors, including the level of cash needed to continue our research program, fulfill our obligations under license agreements, or fund initial production efforts.

We intend to retain future earnings, if any, to retire any existing debt, finance the expansion of our business and any necessary capital expenditures, and for general corporate purposes.

The Company estimates that it will cost approximately $9,000,000 in deficit cash flows through 2014 until sustained potential profitability, and that substantial additional costs will be incurred in order to commercialize its Shrink related technologies.  The Company is not aware as to how much, if any, of these funds will be obtainable from government grants or offset by joint venturing development of our products.
 
Operating activities
 
Net cash used in operating activities was $527,900 for the nine months ended September 30, 2010, as compared to $286,298 used in operating activities during the same period in 2009.  The increase in net cash used in operating activities was mainly due to an increase in business operations, research and development activities and a lack of revenue.
 
Investing activities
 
Net cash used in investing activities for the nine months ended September 30, 2010 was $82,707, as compared to $57,164 net cash used in investing activities through September 30, 2009. The net cash used in investing activities was mainly attributable to patent pending and other intangible asset acquisitions.
 
 
 
Page 10

 
 
 
Financing activities

Net cash provided by financing activities for the nine months ended September 30, 2010 was $555,000, as compared to $387,500 net cash provided by financing activities for the nine months ended September 30, 2009. The increase of net cash provided by financing activities was mainly attributable to financing efforts made by management in order to obtain certain assets, maintain current business operations and research and development activities.

Trends

To a great extent, we expect government grants and university/academic funding to be cyclical based on public policy (e.g. stem cell research limitations), the amount allocated by governments and universities generally to commercial and developmental research, and general economic trends. We expect that we will have to compete diligently in order to secure grants and research funding from universities.  We also anticipate that, for the foreseeable future, our ability to attain conventional bank or secured financing for our products will be difficult as a result of our limited fungible assets and banking constraints that limit commercial loans available to weaker balance sheet companies like Shrink.  We are a cash-deprived company and must secure cash in order to operate going forward.  Capital raising activities will likely be dilutive to our shareholders.

Plan of Operations; Primary Assets and License Rights

Research Agreement with UC Merced
 
Shrink is a party to a research agreement with UC Merced, which agreement is referred to in this Report as the Research Agreement.  Pursuant to the Research Agreement, UC Merced agreed to undertake a research project and Shrink agreed to reimburse it for all direct and indirect costs incurred in connection with the research, up to the amount of $640,935 and in accordance with an agreed-upon budget.  The Research Agreement provides Shrink with the right to elect to receive an exclusive royalty-bearing license to make, use, sell, offer for sale and import any products and practice any methods in the inventions or discoveries conceived and reduced to practice in the performance of the research conducted under the Research Agreement.  We have exercised our rights under this agreement and entered into a license agreement with the UC Regents.  On May 7, 2010, pending a review by our executive and management team, we requested that UC Merced temporarily halt all expenditures under the UC Merced Research Agreement.  Subsequent to the aforementioned review, going forward, Shrink management does not foresee conducting and therefore funding research under its current agreement with the UC Regents related to the Merced campus.  This Agreement and the below license agreement were subsequently terminated as disclosed in our annual report for the year ended December 2010 and Current Reports due to inadequate funds and poor results.

Our Existing (April 2009) Exclusive License Agreement
 
The underlying intellectual property and patent rights to Shrink’s proprietary technologies are owned by the UC Regents and licensed to us.  On April 29, 2009, and pursuant to the terms of the Research Agreement, Shrink and the UC Regents entered into an Exclusive License Agreement for Processes for Microfluidic Fabrication and Other Inventions, which is referred to in this Report as the License Agreement.  The License Agreement licenses a broad array of intellectual property and inventions vital to our planned operations.  The following description of the License Agreement are the material terms of the agreement, and is qualified in its entirety by the actual agreement which is filed as an Exhibit to our Current Report on Form 8-K, filed June 5, 2009.

The term of the License Agreement commenced April 29, 2009 and will continue in effect until the expiration or abandonment of the last patent covered by the agreement, unless we terminate it on 60 days’ notice or the UC Regents terminated it on 60 days’ notice if we default on our obligations under the agreement and fail to cure such default during the 60 day period.

In accordance with the License Agreement, we will be required to pay royalties based on net sales of each licensed product, licensed method or licensed service by the Shrink, any of its affiliates or joint-ventures.  The License Agreement requires that we pay royalties from all income, which includes gross proceeds of all income (other than certain royalties required to be paid by our sub licensees, if any), whether in cash or other considerations and, whether paid to Shrink or its affiliates or assigns, but explicitly excluding, among other things, revenues or receipts from debt or equity financings, or reimbursements for our R&D activities or actual patent prosecution costs.

Our fees to the UC Regents under the License Agreement include:

 
·  
A $100,000 contract initiation fee, which was paid to the Regents during June 2009 in the form of 495,500 shares of common stock of the Company.
 
·  
A  $25,000 annual maintenance fee, unless, (i) by the time that such annual maintenance fee is due, Shrink has already commercialized its principal product and begun paying earned royalties; or (ii) the Company maintains the Research Agreement or another research agreement at the University of California, Merced.
 
·  
A fee of 30% of all income attributed to revenues from a sublicensed product or technology;
 
·  
Milestone payments of $100,000 for total accumulated nets sales of $50,000,000; $500,000 for accumulated  net sales of $150,000,000; and $2,000,000 for net sales of $500,000,000; and
 
·  
Earned royalty payments based on net sales of licensed products.
 
 
 
Page 11

 

 
A minimum $15,000 earned royalty payment will be due each year following the first commercial sale of a licensed product.  The minimum payment will increase to $20,000 on the first commercial sale of the fourth licensed product, and by an additional $5,000 after a commercial sale of each additional licensed product.  The minimum payments are payable by February 28 of each year in which they are due.  Earned royalties in excess of the minimums are payable quarterly.

The License Agreement encourages early commercialization of the Licensed Rights, by providing that our earned royalty payments based on revenues shall be set at between 2.5% of net sales in the event that the first commercial sale commences prior to April of 2012; 4% of net sales in the event that the first commercial sale commences after April 2012, but before the April 2015; and 5% of net sales if the first commercial sale commences thereafter.  First commercial sale is defined as bona fide good faith sale of products that are part of our Licensed Rights, in quantities sufficient to meet market demands, and includes sales for any consideration.

If we use the licensed products or methods as research tools, we are required to pay royalties also, at a rate to be agreed upon, but no less than the rate charged by the UC Regents for similar research tools licensed to others.

If we sublicense the licensed intellectual property, we are also required to pay licensing fee of 30% of the gross income from the license, as well as earned royalty payments on sublicensed sold.   This Agreement and the below license agreement were subsequently terminated as disclosed in our annual report for the year ended December 2010 and Current Reports This Agreement and the below license agreement were subsequently terminated as disclosed in our annual report for the year ended December 2010 and Current Reports due to inadequate funds and poor results.

Other Limitations

The license granted by the License Agreement is further subject to the obligations to the U.S. government, under 35 U.S.C. Sections 200-212, including the obligations to report on utilization of inventions under 37 CFR 401.14(h), and is subject to the National Institute Of Health’s “Principals and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources” (64 F.R. 72090 Dec. 1999, as amended).

No assurance can be made that we will be able to continue developing or, if developed successfully, commercialize our technologies licensed through UC Merced.  The foregoing are the material terms of the License Agreement with UC Merced, a copy of which is filled as an exhibit to this Report as incorporated from our Current Report on Form 8-K filed June 6, 2009.

Our Recent Sponsorship Agreements with the UC Regents and Rights to Acquire Additional License Rights

In May 2010, we entered into the Biosensing Research  Agreement with the UC Regents on behalf of the UCI campus.  The Biosensing Research Agreement is for a term of three years or such time as the research is completed, whichever is longer. The Biosensing Research Agreement may be terminated by the Company subject to satisfying appropriate notice requirements required under the agreement.

Sponsorship Costs.  The Biosensing Research Agreement provides, among other things, that the Company will sponsor specified research relating to development of (i) integrated, manufacturable, nonstructured substrates for biosensing and testing of new bioassays as well as assessing viability of other shrinkable materials, and (ii) stem cell tools that use shrinkable plastic microfluidic technologies, each as more fully provided in the Biosensing Research Agreement.  The Biosensing Research Agreement provides that the Company shall sponsor the research costs up to a budget of $632,051, of which $20,000 has been paid to the UC Regents.

The Company’s research sponsorship obligations require it to provide funding (which may be from the Company or other third parties) totaling $632,051 during the three year term of the Biosensing Research Agreement.  Of this amount $202,796 shall be paid during the 12 month period ended April 30, 2011; $211,311 shall be paid during the 12 month period ended April 30, 2012; and the remaining $217,944 shall be paid during the 12 month period ended April 30, 2013.  The foregoing payments are to be paid in quarterly installments of ¼ of the total cash fees payable during such 12 month period.

No assurance can be made that the Company will attain the funding necessary to fulfill its funding obligations under the SRA Agreement or, that the research performed will necessarily produce commercially viable new inventions.  In addition, in addition to other risks and uncertainties discussed by the Company in its reports, no assurance can be made that the Company will be able to fund the patent application of new inventions, if any, or that it will be able to prosecute its patent rights.

Rights to Enter Into Additional License.   In the event that research under the Biosensing Research Agreement yields additional inventions and intellectual property, we have the right to enter into an additional exclusive license agreement with the UC Regents (see “Our Existing (April 2009) Exclusive License Agreement” above).  In order to exercise its rights, we must not be in default of any payment or funding obligation under the SRA Agreement and, must notify the UC Regents of its intent to license the additional intellectual property within nine (9) months of receipt of notice from the UC Regents of the invention.  In addition, among other conditions and limitations, we would be required to pay for patent application and filing costs relating to additional patents licenses and, to prosecute its rights as against third parties.

The license we have the right to enter into under the Biosensing Research Agreement, is substantially similar to the previously disclosed license rights we have with the UC Regents above, except that we are not required to pay an initial license issue fee, or initial legal fee reimbursement of $35,000, and the terms of the annual license fee has changed to a fee of $5,000 for rights to each patent license acquired by us, with an overall license maintenance fee of $10,000 per annum commencing the fourth year after entry into the license (the “License Date”).  In addition, we are required to pay a fee of 30% of certain income generated from third party sublicenses of the additional intellectual property we license as well as royalty payments of: 2.5% of net sales where the first sale occurs within three years after the License Date; 4% of net sales where the first sale occurs between three and six years after the License Date; and 5% of net sales where the first sale occurs beyond six years after the License Date.  In each case, the minimum earned royalty payment paid shall be $15,000 commencing the year of the first commercial sale of the licensed technology, subject to increase, if and as we expand the SRA License to include additional patents from time to time.  A copy of the prospective license is included as an annex to the Biosensing Research Agreement, filed as an exhibit to our Current Report Form 8-K, filed May 7, 2010, and is incorporated by reference herein.
 
 
 
Page 12

 

 
As with other our other intellectual property licenses, even after the Company’s exercise of its exclusive patent rights with respect to any patent, the UC Regents reserves the right to utilize such intellectual property in connection for educational and research purposes, including research conducted for other sponsors.

The foregoing are the material terms of the Biosensing Research Agreement (which includes the form of SRA License annexed thereto), which is filed as an exhibit to this Report, the provisions of which are incorporated by reference herein.

License Agreement with Corning Incorporated

Effective as of July 26, 2010 we entered into an exclusive Patent and Know-How License Agreement (referred to herein as the “Corning License Agreement”) with Corning Incorporated (“Corning”) pursuant to which, among other things, we licensed the exclusive worldwide right to use and sublicense Corning’s patent-pending Modular Microfluidic System and Method for Building Modular Microfluidic System (US PTO Application No. PCT/US2009/001770).

The system being licensed is a fully functional “plug and play” modular microfluidics system that allows for integrated high pressure connectors, electronics and pumps.  This technology, management believes, has various commercial research applications where ultra-fast microfluidic design prototyping is desired, such as biochemical, biomedical and cell-based drug discovery applications.

Exclusivity; Term. The license granted by Corning is for worldwide usage by the Company for a period of at least eight years.  The term may be terminated for cause or insolvency.

While the license is exclusive to the Company, Corning has reserved rights to the underlying technology for future research and development purposes.  In addition, the licensed rights become co-exclusive for the remainder of the term if the Company does not commercialize the licensed technology before the end of July 2014; provided, that the Company would still retain the right of first refusal for any developments made by Corning on the licensed rights during such non-exclusivity period.

In addition, Corning is required to provide limited technical assistance to the Company as reasonably requested by the Company through July of 2012.

Consideration for Patent Rights.  The Corning License Agreement provides for royalty payments to Corning, for products utilizing the licensed rights, during the royalty term, as more fully detailed in the agreement, of 3% of net sales of products utilizing Corning’s licensed technologies, subject to reduction to the extent (up to 50%) that the Company is required to pay royalties to third parties for such products, and 2% of net sales if and to the extent that the license reverts to a non-exclusive one.

The Corning License Agreement allows the Company, during the term, to determine the appropriate course of action to enforce licensed patent rights, and if it does not do so, Corning reserves the rights to do the same and permit the Company the right to contribute half of the costs in exchange for joint prosecution rights.  The Company is required to reimburse Corning for certain prosecution efforts they incur and, Corning may abandon prosecution of any patent rights in any jurisdiction provided that it provides the Company the opportunity to continue prosecution of the same.  The Company’s obligation to reimburse prosecution efforts of Corning terminates during any period that the patent rights become non-exclusive, if ever.

The foregoing is a summary only of the material terms of the Corning License Agreement, a full copy of which is filed as a copy to this Report.

Off-Balance Sheet Arrangements

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, and results of operations, liquidity or capital expenditures.

FIGATM Ownership

The trademark FIGATM and the domain name www.figa.org are owned by Noctua Fund Manager, LLC, an entity equally owned by Mark L. Baum, Esq. and James B. Panther, II, both directors and majority shareholders of the Company.  The Company presently does not pay for the use of the FIGATM trademark.  The branding of Shrink as a “FIGA business” has been widely used and the Company believes important to explaining Shrink’s business model of using an “expert network” in order to develop Shrink’s operational activities.  In the future, the Company may be required to pay for the use of the FIGATM brand.

Contractual Obligations

The Company (on its own or through its subsidiary) is a party to the License Agreements, Research Agreement with UC Merced, the Sponsored Research Agreements and more recent Corning Agreement mentioned above and incorporated herein, as well as to its strategic Marketing Agreement described above and incorporated by reference herein.  The Company does not have all of the funds necessary to fund these agreements or to commercialize its products and no assurance can be made that it will raise the capital necessary to do so.  If we do not fund the Research Agreement or SRA Agreement we will also risk loss of the licenses.  The Company also enters into agreements with science consultants and professional service providers calling for payment by issuance of stock in lieu of cash, where able.  Some of these agreements call for cash payments at hourly rates as well, if and as needed and with prior consent of the Company.
 
 
 
Page 13

 
 
 
The Company has not yet, approved hourly cash payments to consultants, but intends on doing so if and as our cash availability increases.

Sublease with Business Consulting Group Unlimited, Inc.

The Company subleases space from Business Consulting Group Unlimited, Inc., an entity owned by two of our directors and majority stockholders, James B. Panther II, and Mark L. Baum, Esq. pursuant to which the Company leases approximately 3,000 square feet of office and administrative space, as well as use of, among other things, internet, postage, copy machines, electricity, furniture, fixtures etc. at a rate of $6,000 per month.  The lease with Business Consulting Group Unlimited, Inc. expired April 30, 2010, and is continuing as a month to month tenancy.   For the nine months ended September 30, 2010 $48,000 had been paid to Business Consulting Group Unlimited, Inc and $6,000 was owed to Business Consulting Group Unlimited, Inc.

Operating Agreement and Services with BGCU, LLC

On May 29, 2009, the Company signed an operating agreement (the “Operating Agreement”) with BCGU, LLC, an entity indirectly controlled by James B. Panther II, and Mark L. Baum, Esq., who are two of our directors and majority control persons, for a fee of $6,000 per month.  During October 2009, the Company amended the Operating Agreement with BCGU, LLC.  The amended Operating Agreement (“the “Amended Operating Agreement”) allows us to retain certain day-to-day administrative services and management in consideration of a monthly fee of $30,000 per month.  The Amended Operating Agreement also included a $270,000 signature bonus.  The Amended Operating Agreement expires October 1, 2012.  For the nine months ended September 30, 2010 $101,333 had been paid to BCGU, LLC and there was $508,667 owed to BCGU, LLC.  There is an option within the Amended Operating Agreement that allows BCGU, LLC to convert outstanding payables related to the Operating Agreement into a 10% convertible note.  Because BCGU, LLC is (i) substantially managing the affairs of the company, (ii) is familiar with the affairs of the Company and its strategic direction, (iii) is receiving minimal cash compensation for its efforts and is deferring most payments, the Company believes that the transactions are no less favorable to the Company than would otherwise be available from independent third parties, the Company believes, based on review of its independent directors, that the foregoing transactions and agreements are no less favorable (or even more favorable, given the flexibility) to the Company than would otherwise be available from independent third parties.

The Company has also incurred debt in order to fund its operations, as discussed above and elsewhere in this report in respect of $117,000 of 12% convertible notes issued in November 2010, $635,000 of 12% convertible notes issued between November 2009 and May 2010 (with $535,000 of Notes issued during the nine month period ended September 30, 2010), and $238,121 of debt funded by Noctua Fund L.P. to the Company or its Shrink subsidiary since 2008, as evidenced by the three 14% Convertible notes, in the aggregate principal amount of $118,121, $100,000, and most recently, $20,000 respectively. Some of our notes and related obligations include, in aggregate:
 
·  
$752,000 principal amount of unsecured 12% convertible notes, initially convertible at $.10 per share, into an aggregate of 7,520,000, in addition to shares that may be issued in respect of interest payments, and
 
·  
3,175,000 shares issuable upon exercise of Series A Common Stock Purchase Warrants issued between November 2009 and May of 2010, at $.20 per share, and
 
·  
585,000 shares issuable upon exercise of Series B Common Stock Purchase Warrants issued in November 2010, at $.20 per share, and
 
·  
$118,121.28 principal amount of 14% convertible promissory note, issued to Noctua Fund, L.P. in May 2009, an affiliate of Messers Baum and Panther, II, convertible at $.04 per share into an aggregate of 2,953,032 shares (or 3,519,030 inclusive of 565,998 shares underlying $22,640 of accrued interest, through October 31, 2010), which note is currently in default,
 
·  
$100,000 principal amount of 14% convertible promissory note issued to Noctua Fund, L.P., an affiliate of Messers Baum and Panther, II, reflecting loans made by it in 2008 and 2009, convertible at $0.04 per share into an aggregate of 2,500,000 shares (or 2,979,167 shares inclusive of 479,167 shares underlying $19,167 of accrued interest, through October 31, 2010), which note is also currently in default,
 
·  
$20,000 principal amount of 14% convertible promissory note issued to Noctua Fund, L.P., an affiliate of Messers Baum and Panther, II, reflecting loans made by it in 2010, convertible at $0.04 per share into an aggregate of 500,000 shares (or 505,833 shares inclusive of 833 shares underlying $233 of accrued interest, through October 31, 2010.
 
The $118,121 principal amount note and $100,000 principal amount note to Noctua Fund, L.P. are currently in default. While Noctua Fund, L.P. has irrevocably waived certain anti dilution provisions due to unenforceability and intent, the Notes are otherwise enforceable, with interest and reimbursement of enforcement costs.  The holder of this Note, or its future assigns, may seek to enforce repayment of the note and all enforcement costs in court, which would likely result in a judgment against the company which, among other remedies, could be enforced by levying against our assets or bank accounts.   To the extent we lose some or all of our assets, we would be unable to operate, function and raise capital.  In addition, the mere existence of an event of default could hinder our ability to raise capital or enter into joint ventures or similar obligations.

Moreover, the notes held by Noctua Fund, L.P. are convertible into over 7,000,000 shares as of the date hereof, at $.04 per share, which would be highly dilutive to persons buying our shares in the open market or who have invested in shares or convertible securities of the Company and higher conversion or exercise prices.   Accordingly, the conversion of the Notes and resale of the shares could have a material adverse affect on the company and its share price.

Agreements for Consulting Services
 
The Company strives to save liquid capital by paying for services or satisfying liabilities, whenever able, by issuance of stock to consultants, services providers and consultants.  The issuance of restricted stock in lieu of cash payment sometimes requires that the company pay a premium for such services.  Management believes, nonetheless, that given credit crisis, and difficulty in raising capital for R&D companies such as our own, that the benefits of issuing restricted stock for services outweigh the downside in that it leaves cash available to satisfy debts with vendors where able.  Below is a list material agreements entered into with consultants for services, all of which consultants are independent parties.
 
 
 
Page 14

 
 
 
In March of 2010, we issued 7,250,000 shares valued at $1,232,500 to a consultant in satisfaction of a one year consulting agreement originally entered into in January, 2010 for assistance in developing the Company’s biotech and related products and, in providing research, prototype and product development assistance on our life sciences related products as well instructional videos and materials for use in academic and corporate laboratories.  The agreement is renewable by the parties for successive one-year periods and provides, among other things, for cash compensation at $250.00 per hour commencing only after June 4, 2010, for services if and as requested and agreed to by the Company.  This agreement also provides that any inventions or intellectual property created or discovered by the consultant during the course of providing services for the Company shall belong to the Company and also provides for indemnification by the consultant for damages from claims brought as a result of the consultant’s violation of law or fraudulent misrepresentations or breach of the agreement.
 
In March of 2010, we issued 8,700,000 shares valued at $1,479,000 to a consultant in satisfaction of a consulting agreement entered into in January of 2010, for public relations, assistance with press releases and branding, marketing awareness programs, procurement of third party research and web/statistical content and investor relations. The agreement provides, among other things, that any inventions or intellectual property created or discovered by the consultant during the course of providing services for the Company shall belong to the Company and also provides for indemnification by the consultant for damages from claims brought as a result of the consultant’s violation of law or fraudulent misrepresentations or breach of the agreement.
 
In March of 2010, we issued 1,500,000 shares valued at $255,000 to a consultant in satisfaction of a consulting agreement entered into in February of 2010, for services relating to marketing of our medical device products, and marketing to researches, academia and medical professionals. The agreement is renewable by the parties for successive one-year periods and provides, among other things, for cash compensation at $250.00 per hour commencing only after July 15, 2010, for services if and as requested and agreed to by the Company.  This agreement also provides that any inventions or intellectual property created or discovered by the consultant during the course of providing services for the Company shall belong to the Company and also provides for indemnification by the consultant for damages from claims brought as a result of the consultant’s violation of law or fraudulent misrepresentations or breach of the agreement.
 
In March of 2010, we issued 600,000 shares, subject to lock-up and release restrictions based on continued services over a 3 year period ended March 1, 2013, valued at $102,000 to an accounting professional for previous and ongoing accounting, SEC compliance and financial statement preparation and compilation and related services.
 
In March of 2010, we issued 180,000 restricted shares valued at $30,600 to a consultant in satisfaction of a consulting agreement entered into in March 2010, for services rendered.
 
In March of 2010, we issued 112,500 restricted shares valued at $19,125 to a member of the Scientific Advisory Board, pursuant to an agreement dated as of March 1, 2010.
 
In March of 2010, we issued 40,000 restricted shares valued at $6,800 (in addition to 60,000 shares issued in November 2010) as payment for professional services rendered. No additional amounts are owed for services under this agreement for said time period.
 
In May of 2010, we issued 40,000 shares valued at $8,000 as payment for professional services rendered.
 
In May of 2010, we issued 50,000 shares valued at $10,500 as payment for marketing services related to press releases and branding. No additional amounts are owed under this agreement for said period.
 
In May of 2010, we issued 1,000,000 restricted shares valued at $204,000 to Dr. Sayatani Ghosh, a member of the Scientific Advisory Board (“SAB”) since 2009, pursuant to her agreement dated March 1, 2009.  This agreement has expired by its terms and no additional amounts are owed under said agreement.
 
In July of 2010, we issued 40,000 restricted shares valued at $6,400 as full payment for professional services rendered during the months of June and July.  No additional amounts are owed for these months of service under this agreement.
 
In July of 2010, pursuant to a consulting agreement entered into as of June 1, 2010, we issued 76,364 restricted shares valued at $12,000 as payment for solar research and film manufacturing related consulting services rendered during the months of June and July.  The consulting agreement is for a one year term and requires payment of a monthly fee of $6,000 to be paid in shares of common stock of the Company for the duration of the term unless terminated early.
 
In July of 2010, we issued 395,833 restricted shares valued at $92,625 as payment for financial advisory related services, and development of financial models and due diligence research from December 2009 through May of 2010.  In addition, the Consultant was paid cash compensation of $27,708 in 2010. No additional amounts are owed under said agreement.
 
Some of the agreements under which these shares were issued were not originally committed to a writing and were entered into based on an oral agreement between the independent contractor(s) and a company representative and subsequently memorialized. These shares are cancellable based on performance of said independent contractor.
 
 
 
Page 15

 
 
 
The foregoing agreements do not require us to make further issuances (except for the issuances for professional services which continue insofar as such persons continue to provide services and agree to accept shares in lieu of cash payment.  The foregoing are the material terms of the foregoing agreements, copies of which, to the extent material, are annexed as exhibits to this Report.
 
All stock issuances are subject to Board approval.
 
Lease For Space At University Of California- Irvine, TechPortal™

In September 2010, the Company entered into a lease for laboratory space with the University of California, Irvine (UCI) TechPortal™ technology facilitator center, which lease commences November 1, 2010.  The lease provides approximately 150 square feet of laboratory space and certain equipment and shared office space that will be used for the Company’s UCI developed patents under the Company’s exclusive license agreement with UCI entered into in April of 2009.  The lease is for a minimum of six (6) months and may be extended for another 24 months and may be extended thereafter by the discretion of the parties,  and provides for rent to be paid by the Company of $5,400 per year with each party required to bear the costs of their own insurance and related expenses.  The Company did not effectively commence utilizing this space until November of 2010 and still maintains its corporate headquarters at Carlsbad, California.  The foregoing is a summary only of this lease, a copy of which is filed as an exhibit to this Report.

Recent Accounting Pronouncements

We are not aware of any additional pronouncements that materially effect our financial position or results of operations.

Research and Development
 
The Company estimates that at least $165,918 was spent during nine months ended September 30, 2010, as compared to $73,554 during the same period in 2009 on R&D activities.   During the three months ended September 30, 2010 the Company estimates it spent $32,777, as compared to $0 during the same period in 2009 on R&D activities.  The increase is due primarily to our new Sponsored Research Agreements and other License Agreement as well as our commercialization efforts.

Employees
 
We currently do not have any full time employees.  We obtain most of our administrative services from BCGU, LLC, or BCGU, an entity indirectly controlled by James B. Panther II, and Mark L. Baum, Esq., who are two of our directors, for a fee of $30,000 per month pursuant to an operating agreement and lease space through an affiliated entity, the Business Consulting Group Unlimited, Inc. on a month to month bases (see “Properties” below).  The foregoing are certain material terms of our amended operating agreement with BCGU, LLC, a copy of which is provided as an exhibit to this Report as incorporated from our Form 10-Q, Filed November 25, 2009.

We hire independent contractor labor on an as needed basis and have entered into consulting arrangements with certain directors and advisory board members in exchange for stock or derivative securities. We have not entered into a collective bargaining agreement with any union.

Properties
 
The Company subleases space from Business Consulting Group Unlimited, Inc., an entity owned by two of our directors, James B. Panther II, and Mark L. Baum, Esq. pursuant to which the Company leases approximately 3,000 square feet of office and administrative space, as well as use of, among other things, internet, postage, copy machines, electricity, furniture, fixtures etc. at a rate of $6,000 per month.  The lease with Business Consulting Group Unlimited, Inc. expired April 30, 2010 and the company currently leases the space based on a month to month tenancy.   The foregoing are the material terms of our sublease with Business Consulting Group Unlimited, Inc., a copy of which is attached as an Exhibit to our Current Report Form 8-K, Filed June 5, 2009, the provisions of which are incorporated by reference herein.

The Company also more recently entered into a lease at the UCI Tech Portal for approximately 150 square feet of laboratory space and certain equipment and shared office space that will be used for the Company’s UCI developed patents under the Company’s exclusive license agreement with UCI entered into in April of 2009.  The lease is for a minimum of six (6) months and may be extended for another 24 months and may be extended thereafter by the discretion of the parties, and provides for rent to be paid by the Company of $5,400 per year for up to 30 months.  The foregoing are the material terms of our lease with the UCI Tech Portal, a copy of which is attached as an Exhibit to our Current Report Form 8-K, Filed November 1, 2010, the provisions of which are incorporated by reference herein.

Hedging and Derivative Activities

As at September 30, 2010, and, at October 31, 2010, we have not entered into any type of hedging or interest rate swap transaction.  We do not have any foreign operations or research activities, and, management believes, we do not have exposure to financial product risks.


 
Page 16

 


Item 4.  Controls and Procedures.

As required by Rule 13a-15 under the Securities Exchange Act of 1934 (“Exchange Act”) we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2010, being the date of our most recently completed fiscal quarter.  This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer.  Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures of internal control over financial reporting are not effective at the reasonable assurance level based on those criteria. In addition to the following weakness described below, management concluded the Company did not have an effectively-designed control in operation over the accounting for, presentation of and disclosure of proper expense recognition to prevent or detect on a timely basis material misstatements, specifically with respect to the Company’s prepaid expenses that had been included as an asset in the Company’s consolidated balance sheets.

Insufficient segregation of duties in our finance and accounting functions due to limited personnel.  
  
Insufficient corporate governance policies

For additional information regarding the restatements of certain of the company’s historical financial results and the material weakness identified by management, see Note 2 to the Notes to Consolidated Financial Statements, and “Item 9A. Controls and Procedures” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

We intend to take appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies and we intend to consider the results of our remediation efforts and related testing as part of our next year-end assessment of the effectiveness of our internal control over financial reporting.  To that end, in October of 2009, we formed an Audit Committee of the Board of Directors and adopted an audit committee charter and, in April of 2010 appointed two members of our board, Marshall Khine and Victor Hollander to the Audit Committee.  Due to limited number of board members, this audit committee is not comprised of 3 or more exclusively independent board members, nonetheless, said committee operates independently from the board as contemplated by the Audit Committee charter and this committee was tasked with oversight of selection of the Company’s new independent auditors for the financial statements for year ended December 2010.  The Company intends on further staffing and adapting this committee if and as new qualified board members with accounting experience or knowledge are appointed from time to time.

During our most recently completed quarter ended September 30, 2010, there were no changes in our internal control over financial reporting that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
Page 17

 


PART II - OTHER INFORMATION
 
Item 1. Legal Proceedings.
 
None.

Item 1A. Risk Factors
 
We have not yet commercialized products from our ShrinkChip™ related technologies and therefore have not attained revenues from them.  The nature of our business activities subjects us to certain hazards and risks and uncertainties.  We are a research and development stage company that will need substantial additional capital and development to be able to commercialize and gain market acceptance for our innovative products.  You should carefully consider the risk factors and all of the other information included in, or incorporated by reference into, this Report or any supplement, including those included in our most recent Reports or documents provided as exhibits to this Report or other Reports as may be incorporated from time to time.
 
Our independent accounting firm and our board of directors, given the present resources and condition of the company agree that our internal controls are ineffective and that we may not be able to continue as a going concern.  We are taking steps to correct our internal controls and are also moving to improve the financial condition of the company.

The below risks speak as of September 30, 2010, and have been updated materially in subsequently filed reports specifically, and without limitation, as provided in our Annual Report on Form 10-K for the year ended December 31, 2010 and subsequent reports, as a result in significant business developments and changes.

General Risks:

We may not be able to continue operations as a going concern and we need substantial additional capital to continue our research and development activities and begin commercialization plans.  Research and Development costs of Shrink have been completely paid for to date by the UC Regents, and to a lesser extent, CIRM and, we do not have any capital commitments at this time.

Our independent auditors have expressed doubt about ability to continue as a going concern.  Shrink is currently a research and development company only.  We do not have grant or capital commitments at this time and previous Shrink research has been funded by the UC Regents and CIRM.  We do not believe that the sale of our remaining AudioStocks business related assets or from recent capital raises will be sufficient to fund our operations or research to any material degree.  Nonetheless, we have no further commitments for grants and grant funds cannot, generally, be used towards commercialization and manufacturing efforts.  Accordingly, the corporation will be dependent on obtaining additional external sources of capital in order to fund its operations or even continue as a going concern.

A future capital raise could involve a private or public sales of equity securities or the incurrence of additional indebtedness. Additional funding may not be available on favorable terms, or at all.  If we borrow additional funds, we likely will be obligated to make periodic interest or other debt service payments and may be subject to additional restrictive covenants. If we fail to obtain sufficient additional capital in the future, we could be forced to curtail our growth strategy by reducing or delaying capital expenditures, selling assets or downsizing or restructuring our operations.  If we raise additional funds through public or private sales of equity securities, the sales may be at prices below the market price of our stock, and our shareholders may suffer significant dilution as a result of such sale.

You will suffer immediate and subsequent dilution; and the costs of the securities you may purchase significantly exceed the price paid by current principal shareholders.

Many of the present owners of our issued and outstanding securities acquired such securities at a cost substantially less than that of the open market.  In addition, the Company currently is indebted to Noctua Fund, LP for loans made to the Company or Shrink since 2008, as reflected on three 14% convertible promissory notes in the aggregate initial principal amounts of $118,121, $100,000, and $20,000respectively, plus interest, which are convertible at $.04 per share based on conversion prices at the times of the loans (approximately 7,000,000 shares, in aggregate as of October 31, 2010), both of which are currently in default.  Therefore, the shareholders will bear a substantial portion of the risk of dilution and losses.

Some of our debt is in default and could result in us losing some or all of our assets.

The “default” status with respect to the notes owned by Noctua Fund L.P., an affiliate of certain management, provides them with the right to take potentially aggressive actions, including levying on some or all of our assets, in order to recover monies owed.  This default could result in an action against us, including, one for enforcement of their rights by levying our assets.  The existence of a default also hinders our ability to raise additional capital or enter into long term contractual commitments.

If we do not have funds to fund our Research Agreement, License Agreement and SRA Agreement, we would likely lose some or all of the underlying assets.

The UC Regents contracts specifically provide for budgets which we are required to fund.  If we do not maintain our obligations to fund this research we could lose one or more of our rights under these agreements, including, without limitation, the right to license or sublicense additional or existing patents and intellectual property rights.

 
 
Page 18

 

 
Certain members of management collectively own or have the right to acquire at low rates, 85% of our Common Stock.  In addition to other risks relating to control by such persons of the Company and conflicts of interest, the sale of such shares by management from time to time, will likely have an adverse affect on our stock price.

Our common stock only recently began trading, and trades at fluctuating rates, prices and volumes.  Certain members of Management, namely, Messrs. Baum, Panther and Khine, directly and indirectly own, or have the right to acquire within 60 days, approximately 144,000,000 shares of our common stock constituting approximately 85% of our company after issuance to them.  The holding period on most of these securities under Rule 144 of the Securities Act, has accrued or is nearly accrued and many of these shares are or will be eligible for resale from time to time, subject to volume limitations.  The sale of even a portion of these shares by management will likely have a material adverse affect on our stock price and, will be highly dilutive to shareholders.

In addition to the above risks, the ownership and control by management of such a large block of shares creates inherent conflicts of interest and, results in control of the Company by such persons, as discussed elsewhere in these risk factors.  No person should consider an investment in the Company unless they fully understand the adverse effect that sales by management could have on our stock price and, further, should only invest if they understand the risks associated with control by management.

Management owns a controlling interest of our stock, including, without limitation, our Series A Preferred Stock; the existence of these derivative securities, may adversely affect your stock price and our ability to raise capital or into business ventures and transactions.
 
Currently, twenty million shares (20,000,000) of Series A Preferred Stock are issued and outstanding and held by certain principal shareholders or their affiliates, namely Messrs. Baum and Panther, II.  These shares are all convertible and contain other restrictive covenants.  As a result, over 90% of our voting control is vested in three beneficial owners.  Moreover, as shares of preferred stock are converted and sold, such sales are likely to have a highly dilutive effect on our stock price.

Additionally, the existence of our outstanding preferred stock may hinder our ability to raise capital at favorable prices if and as needed, or to make acquisitions.

As a result, these members of management will be able to:

·  
control the composition of our board of directors; control our management and policies;
 
·  
determine the outcome of significant corporate transactions, including changes in control that may be beneficial to stockholders; and
 
·  
act in each of their own interests, which may conflict with, or be different from, the interests of each other or the interests of the other stockholders.
 
 
Our principal stockholders have the ability to exert significant control in matters requiring stockholder vote and could delay, deter or prevent a change in control of our company.
 
 Since our stock ownership is concentrated among a limited number of holders, those holders have significant influence over all actions requiring stockholder approval, including the election of our board of directors.  Specifically, these members of management are Marshall Khine, Esq., Mark L. Baum and James B. Panther, II (director only).  Through their concentration of voting power, they could delay, deter or prevent a change in control of our company or other business combinations that might otherwise be beneficial to our other stockholders.  In deciding how to vote on such matters, they may be influenced by interests that conflict with other stockholders. Accordingly, investors should not invest in the Company’s securities without being willing to entrust the Company’s business decisions to such persons.

Conflicts of interest between the stockholders and our company or our directors could arise because we do not comply with the listing standards of any exchange with regard to director independence.

There are a variety of conflicts of interests and related party transactions with members of management, which control the vast majority of our shares and our board.  We are not listed on a stock exchange and our Board of Directors does not comply with the independence and committee requirements which would be imposed upon us if we were listed on an exchange.  In the absence of a majority of independent directors, our directors could establish policies and enter into transactions without independent review and approval. This could present the potential for a conflict of interest between the stockholders and our company or our directors.

We have a significant amount of preferred stock, convertible debt and warrants outstanding.  If we issue additional shares or derivative securities as we raise capital, the notes are converted or the warrants are exercised, you will suffer immediate and substantial dilution to your common stock.
 
 
 
Page 19

 

 
The bylaws allow the board to issue common shares without stockholder approval.  Currently, the board is authorized to issue a total of 475,000,000 common shares, of which less than 45% have been issued or reserved for issuance as of April 2010.  In addition, the board is authorized to issue up to 25,000,000 preferred shares of which 20,000,000 are already designated and issue and an addition 5,000,000 “blank check” preferred may be issued.  Currently, 192,906,182 shares of common stock are issued and outstanding and, the following securities are outstanding:

·  
20,000,000 shares of Series A Preferred Stock, owned primarily by Messers Baum and Panther, II, convertible on a one-for-one basis into common stock,
 
·  
$752,000 principal amount of unsecured one year 12% convertible notes, initially convertible at $.10 per share, into an aggregate of 7,520,000, in addition to shares that may be issued in respect of interest payments which notes become due commencing November of 2010, and
 
·  
3,175,000 shares issuable upon exercise of Series A Common Stock Purchase Warrants issued between November 2009 and May of 2010, at $.20 per share, and
 
·  
585,000 shares issuable upon exercise of Series B Common Stock Purchase Warrants issued in November 2010, at $.20 per share, and
 
·  
$118,121.28 principal amount of 14% convertible promissory note, issued to Noctua Fund, L.P. in May 2009, an affiliate of Messers Baum and Panther, II, convertible at $.04 per share into an aggregate of 2,953,032 shares (or 3,519,030 inclusive of 565,998 shares underlying $22,640 of accrued interest, through October 31, 2010, which note is currently in default,
 
·  
$100,000 principal amount of 14% convertible promissory Note issued to Noctua Fund, L.P., an affiliate of Messers Baum and Panther, II, reflecting loans made by it in 2008 and 2009, convertible at $0.04 per share into an aggregate of 2,500,000 shares (or 2,979,167 shares inclusive of 479,167 shares underlying $19,167 of accrued interest, through October 31, 2010), which note is also currently in default,
 
·  
$20,000 principal amount of 14% convertible promissory Note issued to Noctua Fund, L.P., an affiliate of Messers Baum and Panther, II, reflecting loans made by it in 2010, convertible at $0.04 per share into an aggregate of 500,000 shares (or 505,833 shares inclusive of 833 shares underlying $233 of accrued interest, through October 31, 2010.
 
Sales of a substantial number of shares of our common stock in the public market could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.

In addition, it is not likely that we will be able to raise convertible debt or equity financing without issuing shares at or below market rates, which would cause further dilution to shareholders.  Our board of directors has the authority, without the consent of any of the stockholders, to cause us to issue more shares or our common stock and shares of our preferred stock at such prices and on such terms and conditions as are determined by the Board in our sole discretion.

Moreover, cashless exercise provisions in warrants may have an additional adverse effect on the Company in that we would be required to reflect the value of such warrants as a potential liability to the Company.  No assurance can be made, therefore, that we will be able to raise capital, or, if we do, that the same will not have a material adverse effect on our capitalization or to our balance sheet.

If additional funds are raised through the issuance of equity securities, the percentage of equity ownership of the existing stockholders will be reduced. The issuance of additional shares of capital stock by us would materially dilute the stockholders’ ownership in us.

Presently, we have under-qualified management operating the company.

The present management team is not experienced enough and sufficient in number to realize the potential of Shrink, especially with respect to developing commercial diagnostic device products and solar/alternative energy technologies.  It is very likely that more qualified additional managers, with significantly more specific experience in the businesses we seek to engage in, will need to be hired.  The sooner we can hire these people the better.  These persons will likely require substantial salaries and compensation packages that the company cannot presently afford.  Additionally, there may be substantial fees associated with recruiting new additional or replacement managers.  To the extent that we are unable to ultimately bring managers into the company who are more qualified than our present team, the company and its shareholders will be negatively impacted.

Risks Relating to an Investment in Our Securities:

Anti-takeover provisions in our organizational documents and Delaware law may limit the ability of our stockholders to control our policies and effect a change of control of our company and may prevent attempts by our stockholders to replace or remove our current management, which may not be in your best interests.
 
 
 
Page 20

 

 
There are provisions in our certificate of incorporation and bylaws that may discourage a third party from making a proposal to acquire us, even if some of our stockholders might consider the proposal to be in their best interests, and may prevent attempts by our stockholders to replace or remove our current management. These provisions include the following:

·  
Currently, we have 20 million shares of Series A Preferred Stock outstanding (post Forward Split) and owned primarily by management, all of which contain significant anti-takeover and change of control deterrents.  Additionally, our certificate of incorporation authorizes our board of directors to designate any special priority or preference or other rights of, and issue up to 5,000,000 additional shares of “blank check” preferred stock without stockholder approval and to establish the preferences and rights of any preferred stock issued, which would allow the board to issue one or more classes or series of preferred stock that could discourage or delay a tender offer or change in control;
 
·  
our certificate of incorporation prohibits our stockholders from filling board vacancies, calling special stockholder meetings or taking action by written consent;
 
·  
our certificate of incorporation provides for the removal of a director only with cause and by the affirmative vote of the holders of 75% or more of the shares then entitled to vote at an election of directors; and
 
·  
our bylaws require advance written notice of stockholder proposals and director nominations. Additionally, we are subject to Section 203 of the Delaware General Corporation Law, which, in general, imposes restrictions upon acquirers of 15% or more of our stock. Finally, the board of directors may in the future adopt other protective measures, such as a stockholder rights plan, which could delay, deter or prevent a change of control.
 
Compliance with Sarbanes-Oxley could be time consuming and costly, which could cause our independent registered public accounting firm to conclude that our internal control over financial reporting is not effective.

As a public company, we are required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which will require annual management assessments of the effectiveness of our internal control over financial reporting and a report by our independent registered public accounting firm that both addresses management’s assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting.

During the course of our testing, we may identify deficiencies which we may not be able to remediate in time to meet our deadline for compliance with Section 404. Testing and maintaining internal controls can divert our management’s attention from other matters that are important to our business. We also expect the new regulations to increase our legal and financial compliance cost, make it more difficult to attract and retain qualified officers and members of our Board of Directors (particularly to serve on an audit committee) and make some activities more difficult, time consuming and costly.  We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404.  Our independent registered public accounting firm may not be able or willing to issue an unqualified report on the effectiveness of our internal control over financial reporting.

If we conclude that our internal control over financial reporting is not effective, we cannot be certain as to the timing of completion of our evaluation, testing and remediation actions or their effect on our operations since there is presently no precedent available by which to measure compliance adequacy.

If we are unable to conclude that we have effective internal control over financial reporting or our independent auditors are unable to provide us with an unqualified report as required by Section 404, then we may not be able to raise capital from certain sources, or list on exchanges or the NASDAQ and investors could lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.

Lack of economic review may interfere with investors’ ability to fully assess merits and risks associated with purchase of our stock.

The procurement by prospective investors of an independent review of the investments merits of a proposed subscription for our stock would be costly and can normally be conducted only by those prospective investors whose subscriptions will be of sufficient magnitude that they, either alone or by a pooling of their resources with those of other prospective investors, could afford the expense of such independent analysis, including the retaining of independent consultants. Such a review might or might not prove favorable.  Accordingly, subscription to the stock is suitable only for such proposed investors willing and able to accept the risks created by a failure to conduct an independent analysis of this investment.

We do not anticipate paying cash dividends, which could reduce the value of your stock.

We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.  Even if we do attain revenues and become profitable, we intend on reinvesting profits, if any.  The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting it at such time as our board of directors may consider relevant.  Our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.

There is limited historical information available for investors to evaluate our performance or a potential investment in our shares.

We are a development stage company with little historical information available to help prospective investors evaluate our performance or an investment in our shares, and our historical financial statements are not necessarily a meaningful guide for evaluating our future performance because we have not begun to manufacture and market our products.

Our common stock does not trade in a mature market and therefore has limited liquidity.
 
 
 
Page 21

 

 
Our common stock trades on the over-the-counter market.  The average daily trading volume of our common stock on the over-the-counter market has not been consistent. Our daily volume remains limited and there is no assurance that increased volume, if any occurs, will continue. Holders of the our common stock may not be able to liquidate their investments in a short time period or at the market prices that currently exist at the time a holder decides to sell.  Because of this limited liquidity, it is unlikely that shares of our common stock will be accepted by lenders as collateral for loans.

The Company’s shareholders may face significant regulatory restrictions relating to the sale of their stock, as a result of penny stock and similar rules.

The Company’s stock differs from many stocks in that it is a “penny stock.” The Commission has adopted a number of rules to regulate “penny stocks” including, but not limited to, those rules from the Securities Act as follows:

·  
3a51-1 which defines penny stock as, generally speaking, those securities which are not listed on either NASDAQ or a national securities exchange and are priced under $5, excluding securities of issuers that have net tangible assets greater than $2 million if they have been in operation at least three years, greater than $5 million if in operation less than three years, or average revenue of at least $6 million for the last three years;
 
·  
15g-1 which outlines transactions by broker/dealers which are exempt from 15g-2 through 15g-6 as those whose commissions from traders are lower than 5% total commissions;
 
·  
15g-2 which details that brokers must disclose risks of penny stock on Schedule 15G;
 
·  
15g-3 which details that broker/dealers must disclose quotes and other information relating to the penny stock market;
 
·  
15g-4 which explains that compensation of broker/dealers must be disclosed;
 
·  
15g-5 which explains that compensation of persons associated in connection with penny stock sales must be disclosed;
 
·  
15g-6 which outlines that broker/dealers must send out monthly account statements; and
 
·  
15g-9 which defines sales practice requirements.
 
Since the Company’s securities constitute a “penny stock” within the meaning of the rules, the rules would apply to us and our securities. Because these rules provide regulatory burdens upon broker-dealers, they may affect the ability of shareholders to sell their securities in any market that may develop; the rules themselves may limit the market for penny stocks. Additionally, the market among dealers may not be active. Investors in penny stock often are unable to sell stock back to the dealer that sold them the stock. The mark-ups or commissions charged by the broker-dealers may be greater than any profit a seller may make. Because of large dealer spreads, investors may be unable to sell the stock immediately back to the dealer at the same price the dealer sold the stock to the investor. In some cases, the stock may fall quickly in value. Investors may be unable to reap any profit from any sale of the stock, if they can sell it at all. Shareholders should be aware that, according to Commission Release No. 34-29093 dated April 17, 1991, the market for penny stocks has suffered from patterns of fraud and abuse. These patterns include:

·  
control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer;
 
·  
manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases;
 
·  
“boiler room” practices involving high pressure sales tactics and unrealistic price projections by inexperienced sales persons;
 
·  
excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and
 
·  
the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.
 
Our previous Audiostocks related businesses have dramatically diminished and we do not intend to pursue them in any significant manner. Our Shrink subsidiary is a research and development startup company and has not generated any operating revenues and may never achieve profitability, and we have yet to commercialize its inventions.

We sold the assets relating to our AudioStocks internet based investor relations business in late 2008, with the exception of certain proprietary software which we intend to sell in the future, if possible.  Therefore, we do not have any revenues or significant assets from our prior businesses.
 
 
 
Page 22

 

 
Our recently acquired subsidiary, Shrink, is a risky and unproven development stage company and, to date, has not generated any revenues from sales.  We cannot assure you that we will generate revenues or that we can achieve or sustain profitability in the future.  Our operations are subject to the risks and competition inherent in the establishment of a business enterprise. There can be no assurance that future operations will be profitable.  Revenues and profits, if any, will depend upon various factors, including whether our product development can be completed, and if we can achieve market acceptance.  We may not achieve our business objectives and the failure to achieve such goals would have an adverse impact on us.

Risks Related To Development And Commercialization Of Our Products:

Our technologies are unproven and new. No assurance can be made that our technologies will work as anticipated, or, even if they do work, will be commercially accepted.

We are a primarily R&D company with a newly developing and novel manufacturing technology.  We do not have agreements with purchasers yet and no assurance can be made that we will be able to make our technology viable.  Even if we are able to continue to fund our research and development and make our technologies viable, no assurance can be made that our chips will attain market acceptance in light of the larger, more established competitors in the life sciences and solar industries.  If we are unable to raise sufficient capital or commercialize our unproven products, our stock price will decline and you will be adversely affected.

If we are unable to obtain required clearances or approvals for the commercialization of our products in the United States, we may not be able to sell products and our sales could be adversely affected.

Our future performance depends on, among other matters, our estimates as to when and at what cost we will receive regulatory approval for our products. Regulatory approval can be a lengthy, expensive and uncertain process, making the timing, cost and ability to obtain approvals difficult to predict.

In the United States, clearance or approval to commercially distribute new medical devices is received from the FDA through clearance of a Premarket Notification, or 510(k), or through approval of a Premarket Approval, or PMA. To receive 510(k) clearance, a new product must be substantially equivalent to a medical device first marketed in interstate commerce prior to May 1976.

The FDA may determine that a new product is not substantially equivalent to a device first marketed in interstate commerce prior to May 1976 or that additional information is needed before a substantial equivalence determination can be made.

A “not substantially equivalent” determination, or a request for additional information, could prevent or delay the market introduction of new products that fall into this category. The 510(k) clearance and PMA review processes can be expensive, uncertain and lengthy. It generally takes from three to five months from submission to obtain 510(k) clearance, and from six to eighteen months from submission to obtain a PMA approval; however, it may take longer, and 510(k) clearance or PMA approval may never be obtained.

Modifications or enhancements that could significantly affect safety or effectiveness, or constitute a major change in the intended use of the device, require new 510(k) or PMA submissions.

We may suffer the loss of key personnel or may be unable to attract and retain qualified personnel to maintain and expand our business.

Our success is highly dependent on the continued services of a limited number of skilled scientists, especially, Dr. Michelle Khine and Dr. Heiner Dreismann.  The company does not have an agreement for employment or consulting with Dr. Khine.  We have a consulting agreement with Dr. Dreismann.  In addition, our success will depend upon, among other factors, our ability to attract, retain and motivate qualified research and development, engineering and operating personnel, generally and during periods of rapid growth, especially in those areas of our businesses focused on new products and advanced manufacturing processes. There can be no assurance that we will be able to retain existing employees or to attract and retain additional personnel on acceptable terms.  The competition for qualified personnel in industrial, academic and nonprofit research sectors is significant.

The loss of the services of any of our key research and development, engineering or operational personnel or senior management without adequate replacement, or the inability to attract new qualified personnel, would have a material adverse effect on our operations.

Some of the processes we require in order to commercialize our products are in short supply which may delay commercialization and hinder our development of products.

As an example, we use a process called hot embossing.  The machines that do commercial scale hot embossing are in short supply and are very expensive.  Therefore, we rely on third party contractors in order to assist us with prototype commercial scale production and will also perhaps rely on these same parties for larger scale production, assuming there is market acceptance.  The costs of using these parties may significantly reduce our profit margins, and to the extent we decide to purchase our own equipment to build a manufacturing line, such an effort will not only take time, but will also amount to a significant risk of capital to the Company given our limited resources.
 
 
 
Page 23

 

 
Significant existing or additional governmental regulation could subject us to unanticipated delays and costs, which would adversely affect our revenues.
        
Our products are still in the development stage.  However certain products which we may produce may be subject to government regulation depending upon their ultimate use. The successful implementation of our business strategy depends in part on our ability to get our products into the market as quickly as possible. Additional laws and regulations, or changes to existing laws and regulations, applicable to our business may be enacted or promulgated and the interpretation, application or enforcement of existing laws and regulations may change. We cannot predict the nature of any future laws, regulations, interpretations, applications or enforcements, or the specific effects any of these might have on our business. Any future laws, regulations, interpretations, applications, or enforcements could delay or prevent regulatory approval or clearance of our products and our ability to market our products. Moreover, if we do not comply with existing or future laws or regulations, we could be subject to the following types of enforcement actions by the FDA and other agencies:

·  
Fines;
 
·  
Injunctions;
 
·  
Civil penalties;
 
·  
Recalls or seizures of our products;
 
·  
Total or partial suspension of the production of our products;
 
·  
Withdrawal of existing approvals or premarket clearances of our products;
 
·  
Refusal to approve or clear new applications or notices relating to our products;
 
·  
Recommendations by the FDA that we not be allowed to enter into government contracts; and
 
·  
Criminal prosecution.
 
We rely in part, on UC Merced and the UC Regents to file and secure our patents.

In addition to the option agreement with the UC Regents, Shrink has entered into a research and development agreement with UC Merced in order to fund certain research based on the intellectual property we have licensed and have the right to license from the UC Regents.  The agreement with UC Merced provides Shrink with an exclusive opportunity to license any technology that flows (derivative IP) from the research Shrink funds at UC Merced.  Should any intellectual property flow from this research and development agreement and Shrink elects to exercise such rights, it will be required to make annual payments to the UC Regents as well as royalty payments as commercialization occurs.

Under our research and development agreements we rely on third party laboratories that can experience manufacturing problems or delays, which could result in decreased revenue or increased costs.
 
All of our research and development agreements require processes that are complex and require specialized and expensive equipment. Replacement parts for this specialized equipment can be expensive and, in some cases, can require lead times of up to a year to acquire. There can be no assurance that our funding commitment under the UC Merced research and development agreements will be adequate to fund the equipment requirements.  We also rely on numerous third parties to supply production materials and in some cases there may not be alternative sources immediately available, or they may not be available at a reasonable cost.

Shrink has substantial risk in being sued with respect to its intellectual property rights.

The world of intellectual property rights is very murky and it is often very difficult to determine the specific abilities of a business to use and exploit intellectual property rights.  Moreover even to the extent a business has solid rights, there could be substantial costs involved in defending ones rights.  Shrink has not completed nor sought any “freedom to operate” opinions from competent intellectual property counsel with respect to its related intellectual property rights and it is reasonably to assume that as the market for Shrink’s products evolves and we produce products for these markets, Shrink will be a target for such lawsuits.  Given our limited resources to defend ourselves, this may be, from a corporate perspective, a “life threatening” scenario.
 
 
 
Page 24

 

 
We will be subject to applicable regulatory approval requirements of the foreign countries in which we could sell products, which are costly and may prevent or delay us from marketing our products in those countries.
 
In addition to regulatory requirements in the United States, we will be subject to the regulatory approval requirements for each foreign country to which could export our products. In the European Union, regulatory compliance requires affixing the “CE” mark to product labeling. Although our new products could be made eligible for CE marking through self-certification, this process can be lengthy and expensive. In Canada, as another example, our new products could require approval by Health Canada prior to commercialization along with International Standards Organization, or ISO, 13485/CMDCAS certification. It generally takes from three to six months from submission to obtain a Canadian Device License. Any changes in foreign approval requirements and processes may cause us to incur additional costs or lengthen review times of our new products, if any. We may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from marketing our products in foreign countries, which may have a material adverse effect on our business, financial condition and results of operations.

We may experience difficulties that may delay or prevent our development, introduction or marketing of new or enhanced products.

We intend to continue to invest in product and technology development. The development of new or enhanced products is a complex and uncertain process. We may experience research and development, manufacturing, marketing and other difficulties that could delay or prevent our development, introduction or marketing of new products or enhancements. We cannot be certain that:

· any of the products under development will prove to be effective in generating sales demand;
 
·  
we will be able to obtain, in a timely manner or at all, regulatory approval, if required, to market any of our products that are in development or contemplated;
 
·  
we are able to find adequate supplies of the necessary component parts for the devices we intend to sell, which is a very challenging risk because we presently do not manufacture anything, relying exclusively on third party company partners and business relationships;
 
·  
the products we develop can be manufactured at acceptable cost and with appropriate quality; or these products, if and when approved, can be successfully marketed.
 
The factors listed above, as well as manufacturing or distribution problems, or other factors beyond our control, could delay new product launches. In addition, we cannot assure you that the market will accept these products.  Accordingly, there is no assurance that our overall revenue will increase if and when new products are launched.

Intense competition could limit our ability to secure market share which could impair our ability to sell our products and harm our financial performance.

The microfluidics, biochip and renewable energy industries, along with nearly every market we seek to penetrate, are new and underdeveloped markets and industries are rapidly evolving, and developments are expected to continue at a rapid pace. Competition in this industry, which includes competition from professional diagnostic, consumer diagnostic and renewable energy businesses, among others, is intense and expected to increase as new products and technologies become available and new competitors enter the market. Our competitors in the United States and abroad are numerous and include, among others, diagnostic testing, medical products and renewable energy companies, universities and other research institutions.

Our future success depends upon maintaining a competitive position in the development of products and technologies in our areas of focus. Our competitors may:

·  
develop technologies and products that are more effective, less expensive, safer or more readily available than our products or that render our technologies or products obsolete or noncompetitive;
 
·  
obtain patent protection or other intellectual property rights that would prevent us from developing potential products; or
 
·  
obtain regulatory approval for the commercialization of our products more rapidly or effectively than we do.
 
As a result, our products or processes may not compete successfully, and research and development by others may render our products or processes obsolete or uneconomical.

Also, the possibility of patent disputes with competitors holding domestic and/or foreign patent rights may limit or delay expansion possibilities. In addition, many of our existing or potential competitors have or may have substantially greater research and development capabilities, clinical, manufacturing, regulatory and marketing experience and financial and managerial resources, giving them a competitive advantage in the markets in which we hope to operate.
 
The market for the sale of our products is also highly competitive. This competition is based principally upon price, quality of products, customer service and marketing support. We believe that a number of our competitors are substantially larger than we are and have greater financial resources, and have a more established sales and marketing force already operating in the market, which would give them a competitive advantage over us.
 
 
 
Page 25

 

 
We must be able to manufacture new and improved products to meet customer demand on a timely and cost-effective basis.

We do not have any manufacturing facilities. We are negotiating with third parties for the development and manufacture of our products initially.  However, even if we are able to develop our products, and penetrate the drug and life science industries, we may have to construct or acquire a manufacturing facility or utilize third parties, both of which would require us to train appropriate personnel.  To build a manufacturing facility, we will need substantial additional capital and we do not have any capital commitments to fund such construction.  In addition, the recent financial crisis has made it extremely difficult to obtain commercial property or industrial financing.  In addition, we must be able to resolve in a timely manner manufacturing issues that may arise from time to time as we commence production of our complex products.  With a start up manufacturing facility, unexpected problems may be more frequent as new equipment is put on line and operators are inexperienced in its operation.  These and other unanticipated difficulties or delays in manufacturing our products during commercialization, in sufficient quantities to meet customer demand could diminish future demand for our products, cause us to incur greater debt and materially harm our business.

A significant portion of our sales will be dependent upon our customers’ capital spending policies and research and development budgets, and government funding of research and development programs at universities and other organizations, which are subject to significant and unexpected fluctuations.
 
Our target markets include pharmaceutical and biotechnology companies, academic institutions, government laboratories, and private foundations. Fluctuations in the research and development budgets at these organizations could have a significant effect on the demand for our products and services. Research and development budgets fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities, general economic conditions, and institutional and governmental budgetary policies. Our business could be seriously damaged by any significant decrease in capital equipment purchases or life sciences research and development expenditures by pharmaceutical and biotechnology companies, academic institutions, government laboratories, or private foundations.
 
The timing and amount of revenues from customers that rely on government funding of research may vary significantly due to factors that can be difficult to forecast.  Research funding for life science research has increased more slowly during the past several years compared to the previous years and has declined in some countries, and some grants have been frozen for extended periods of time or otherwise become unavailable to various institutions, sometimes without advance notice. Although the level of research funding increased significantly during the years 1999 through 2003, increases for fiscal 2004 through 2008 were significantly lower. Government funding of research and development is subject to the political process, which is inherently fluid and unpredictable. Other programs, such as homeland security or defense, or general efforts to reduce the federal budget deficit could be viewed by the U.S. government as a higher priority. These budgetary pressures may result in reduced allocations to government agencies that fund research and development activities. Past proposals to reduce budget deficits have included reduced NIH and other research and development allocations.  Any shift away from the funding of life sciences research and development or delays surrounding the approval of government budget proposals may seriously damage our business.
 
Many of our current and potential competitors have longer operating histories, larger customer or user bases, greater brand recognition, greater access to brand name suppliers, and significantly greater financial, marketing and other resources than we do.

Many of these current and potential competitors can devote substantially more resources to the development of their business operations than we can at present.  Currently, we do not have a marketing or manufacturing infrastructure in place.   In addition, larger, well-established and well-financed entities may acquire, invest in or form joint ventures with other established competitors or with specific product manufacturers, which will allow them pricing advantages due to economies of scale or pursuant to distribution agreements with suppliers. Some large product distributors may also have exclusive distribution agreements or protected territories in which they can sell specific brand name products at a significant discount, or territories in which they may seek to exclude us from selling a specific brand of product. These types of arrangements between our competitors and manufacturers and suppliers may limit our ability to distribute certain products and could adversely affect our revenues. 

There can be no assurance that new products we introduce will achieve significant market acceptance or will generate significant revenue.

The market for products in micro-fluidics, bio-sensing and renewable energy industries is characterized by rapid technological advances, evolving standards in technology and frequent new product and service introductions and enhancements. Possible short life cycles for products we sell may necessitate high levels of expenditures for continually selecting new products and discontinuing the sale of obsolete product lines. To obtain a competitive position, we must continue to introduce new products and new versions of existing products that will satisfy increasingly sophisticated customer requirements and achieve market acceptance.  Our inability or failure to position and/or price our new or existing products competitively, in response to changes in evolving standards in technology, could have a material adverse effect on our business, results of operations or financial position.

If we deliver products with defects, our credibility may be harmed, market acceptance of our products may decrease and we may be exposed to liability.
 
The manufacturing and marketing of our products will involve an inherent risk of product liability claims. In addition, our product development is and production will be extremely complex and could expose our products to defects. Any defects could harm our credibility and decrease market acceptance of our products. In the event that we are held liable for a claim for which we are not indemnified or insured that claim could materially damage our business and financial condition. Even if we are indemnified, we may not be able to obtain reimbursement of our damages from the indemnifying party, because for example they do not have sufficient funds or insurance coverage to pay us.  If a claim is made for which we have insurance coverage, we can not be certain that the amount of such coverage will be sufficient, or that we will be able to collect on a claim when we make it.

Because we have not yet begun to sell our products, we have not obtained insurance covering product liability claims or product recall claims against us.  When we begin to market our products, such insurance may not be available to us, or not available on terms which we find acceptable.   We may determine that the cost of such insurance is too high when compared to the risks of not having coverage and we may determine not to obtain policies insuring such risks, or we may obtain policies with a high deductible.
 
 
 
Page 26

 

 
If we are not able to adequately protect our intellectual property, we may not be able to compete effectively.

Our success depends, to a significant degree, upon the protection of our proprietary technologies. While we currently license certain U.S. patents and patent applications from UC Merced, we may need to pursue additional protections for our intellectual property as we develop new products and enhance existing products and technologies.

We may not be able to obtain appropriate protections for our intellectual property in a timely manner, or at all. Our inability to obtain appropriate protections for our intellectual property may allow competitors to enter our markets and produce or sell the same or similar products.

The risks and uncertainties that we face with respect to our patents and other proprietary rights include the following:

·  
the pending patent applications we have filed or to which we have exclusive rights may not result in issued patents or may take longer than we expect to result in issued patents;
 
·  
the claims of any patents which are issued may not provide meaningful protection;
 
·  
we may not be able to develop additional proprietary technologies that are patentable; the patents licensed or issued to us or our customers may not provide a competitive advantage;
 
·  
other parties may challenge patents or patent applications licensed or issued to us or our customers;
 
·  
patents issued to other companies may harm our ability to do business; and
 
·  
other companies may design around technologies we have patented, licensed or developed.
 
We may need to obtain licenses to patents or other proprietary rights from third parties. We may not be able to obtain the licenses required under any patents or proprietary rights, or they may not be available on acceptable terms. If we do not obtain required licenses, we may encounter delays in product development or find that the development, manufacture or sale of products requiring licenses could be foreclosed.

We may, from time to time, support and collaborate in research conducted by universities and governmental research organizations, such as UC Merced, UC Irvine and MF3 at UC Irvine. We may not be able to acquire exclusive rights to the inventions or technical information derived from these collaborations, and disputes may arise over rights in derivative or related research programs conducted by us or our collaborators.

In addition to patents, we rely on a combination of trade secrets, nondisclosure agreements and other contractual provisions and technical measures to protect our intellectual property rights.  Nevertheless, these measures may not be adequate to safeguard the technology underlying our products. If these measures do not protect our rights, third parties could use our technology and our ability to compete in the market would be reduced. In addition, employees, consultants and others who participate in the development of our products may breach their agreements with us regarding our intellectual property, and we may not have adequate remedies for the breach.

We also may not be able to effectively protect our intellectual property rights in some foreign countries.

In order to protect or enforce our patent rights, we may initiate patent litigation against third parties, such as infringement suits or interference proceedings.  Litigation may be necessary to:

·  
assert claims of infringement;
 
·  
enforce our patents;
 
·  
protect our trade secrets or know-how; or
 
·  
determine the enforceability, scope and validity of the proprietary rights of others.
 
Any lawsuits that we initiate could be expensive, take significant time and divert management’s attention from other business concerns. Litigation also puts our patents, if any, at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing. Additionally, we may provoke third parties to assert claims against us.
 
 
 
Page 27

 

 
Litigation may be necessary to enforce intellectual property rights. Litigation is inherently uncertain and the outcome is often unpredictable. Patent law relating to the scope of claims in the technology fields in which we operate is still evolving and, consequently, patent positions in our industry are generally uncertain. We may not prevail in any and the damages or other remedies awarded, if any, may not be commercially valuable.

For a variety of reasons, for example, because we do not have adequate funds, we may decide not to file for patent, copyright or trademark protection or prosecute potential infringements of our patents. Our trade secrets may also become known through other means not currently foreseen by us. Despite our efforts to protect our intellectual property, our competitors or customers may independently develop similar or alternative technologies or products that are equal or superior to our technology and products without infringing on any of our intellectual property rights or design around our proprietary technologies. Changes in laws concerning intellectual property would affect our ability to protect our intellectual property, if any.

We could suffer monetary damages, incur substantial costs or be prevented from using technologies important to our products as a result of a legal proceedings being commenced against us.

Because of the nature of our business, we may be subject at any particular time to commercial disputes, consumer product claims, negligence or various other lawsuits arising in the ordinary course of our business, including employment matters, and we expect that this will continue to be the case in the future. Such lawsuits generally seek damages, sometimes in substantial amounts, for commercial or personal injuries allegedly suffered and can include claims for punitive or other special damages. An adverse ruling or rulings in one or more such lawsuits could, individually or in the aggregate, have a material adverse effect on our sales, operations or financial performance.  We cannot assure you that any future lawsuits relating to our businesses will not have a material adverse effect on us.

Risks Relating to Our Operations:

We are currently in a growth stage and may experience setbacks in both business and product development.

We are subject to all of the risks inherent in both the creation of a new business and the development of new and existing products.  Our cash flows may be insufficient to meet expenses relating to our operations and the growth of our business, and may be insufficient to allow us to develop new and existing products. We currently so not manufacture or market any product and we cannot be certain that we will ever be able to develop, manufacture, market or sell any product.

We currently do not have adequate insurance coverage for claims against us.

We face the risk of loss resulting from product liability, securities, fiduciary liability, intellectual property, antitrust, contractual, warranty, environmental, fraud and other lawsuits, whether or not such claims are valid.  In addition, we do not have adequate or in some cases, any product liability, fiduciary, directors and officers, property, natural catastrophe and comprehensive general liability insurance.  To the extent we secure adequate insurance it may not be adequate to cover such claims or may not be available to the extent we expect. If we are able to secure adequate insurance our costs could be volatile and, at any time, can increase given changes in market supply and demand. We may not be able to obtain adequate insurance coverage in the future at acceptable costs.  A successful claim that exceeds or is not covered by our policies could require us to pay substantial sums.  Even to the extent we are able to acquire adequate insurance, we may not be able to afford to continue coverage through a policy period or in multiple and successive policy periods.

Although we have implemented safeguards to prevent unauthorized access to our ecommerce sites, there always exists certain security risks, which may cause interruptions, delays or cessation in service.

Despite the implementation of security measures, our network infrastructure may be vulnerable to computer viruses or problems caused by third parties, which could lead to interruptions, delays or cessation in service to our clients. Inappropriate use of the Internet by third parties could also potentially jeopardize the security or deter certain persons from using our services. Such inappropriate use of the Internet would include attempting to gain unauthorized access to information or systems - commonly known as "cracking" or "hacking." Although we intend to continue to implement security measures, such measures have been circumvented in the past, and there can be no assurance that measures implemented will not be circumvented in the future. Alleviating problems caused by computer viruses or other inappropriate uses or security breaches may require interruptions, delays or cessation in service to our operations. There can be no assurance that customers or others will not assert claims of liability against us as a result of failures. Further, until more comprehensive security technologies are developed, the security and privacy concerns of existing and potential customers may inhibit the growth of the Internet service industry in general and our customer base and revenues in particular.
 
 
 
 
 
 
 
 

 
 
Page 28

 
 
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
 
In June and July of 2010, we issued 40,000 restricted shares valued at $6,400 as payment for professional services rendered pursuant to an existing, month to month agreement.
 
In July of 2010, we issued 76,364 restricted shares valued at $12,000 as payment for solar research related consulting services rendered. There are no further liabilities or amounts owed to the consultant under this agreement.
 
In July of 2010, we issued 395,833 restricted shares valued at $92,625 as payment for financial advisory related services, and development of financial models and due diligence research from December 2009 through May of 2010.
 
In November 2010, we sold $117,000 of 12% convertible notes issued in November 2010, and issued 585,000  Series B Common Stock Purchase Warrants issued in November 2010, at $.20 per share to a single accredited investor in a private financing, at a purchase price of $117,000.  The 12% notes are due one year from issuance and are convertible as to principal and interest at $.10 per share.  The form of these notes and Series B Warrants are identical in all respects, to the notes and Series A Warrants issued in 2009, with the exception of the issuance dates and expiration dates.
 
All of the issuances of securities described above were restricted share issuances and deemed to be exempt from registration in reliance on Section 4(2) of the Securities Act of 1933, as amended (the “Act”) or Regulation D, as transactions by an issuer not involving a public offering.  We made the determination that each investor had enough knowledge and experience in finance and business matters to evaluate the risks and merits of the investment.  There was no general solicitation or general advertising used to market the securities and all of the issuees were either affiliates of the Company or had a pre-existing business relationship with the Company.  We made available to each investor with disclosure of all aspects of our business, including providing the investor with press releases, access to our auditors, and other financial, business, and corporate information. A legend was placed on the stock certificates stating that the securities have not been registered under the Securities Act and cannot be sold or otherwise transferred without an effective registration or an exemption there from.
 
Item 3. Defaults Upon Senior Securities.
 
We are in default on payment of interest and principal upon the following notes:  14% Convertible Note with a principal amount of $100,000 owed to Noctua Fund, LP and 14% Convertible Note with a principal amount of $118,121 owed to Noctua Fund, LP, a copy of the notes which were filed as an exhibits to this report as incorporated from our Current Report on Form 8-K, filed May 8, 2009 and our Current Report on Form 8-K, filed June 5, 2009.  During the default period repayment of these notes are accelerated accrue interest at 18% with a total of approximately $281,161 of principal and interest due as at October 31, 2010.

Item 4. Submission of Matters to a Vote of Security Holders.
 
None.

Item 5. Other Information.
 
None.
 
 
 
 
 
 
 
 
 
 
 
 

 
 
Page 29

 
Item 6. Exhibits.

The Following Exhibits are filed herewith

3.1
Certificate of Amendment to Articles of Incorporation (Incorporated by reference from Annual Report on Form 10K for year ended December 31, 2009)
4.1
Form of Convertible Note 12% (Incorporated by reference from Annual Report on Form 10K for year ended December 31, 2009)
4.2
Form of Series A Warrant (Incorporated by reference from Annual Report on Form 10K for year ended December 31, 2009)
4.3
Subscription Agreement (Incorporated by reference from Annual Report on Form 10K for year ended December 31, 2009)
10.1
Exclusive License Agreement for Processes for Microfluidic Fabrication and other Inventions, dated as of April 29, 2009, between Shrink Technologies, Inc., a California corporation and the California Regents of the University of California. (Incorporated by reference from Exhibit 10.2 to Current Report on Form 8-K, filed June 5, 2009)
10.2
Research Agreement between Shrink Technologies, Inc. and the Regents of the University of California. (Incorporated by reference from Exhibit 10.3 to Current Report on Form 8-K, filed June 5, 2009)
10.3
Office space sublease between Shrink Technologies, Inc., a California corporation as Tenant and Business Consulting Group Unlimited, Inc. as sublessor, dated as of May 1, 2009.  (Incorporated by reference from Exhibit 10.4 to Current Report on Form 8-K, filed June 5, 2009)
10.4
Operating Agreement, dated as of May 1, 2009 between Shrink Technologies, Inc., a California corporation, and BCGU, LLC, a Nevada limited liability company. (Incorporated by reference from Exhibit 10.4 to Current Report on Form 8-K, filed June 5, 2009)
10.5
First Amended Operating Agreement. (Incorporated by reference from Exhibit 10.1 to Current Report on Form 10Q, For the Quarter Ended September 30, 2009)
10.6
Debt Consolidation Agreement effective as of April 20, 2009 between AudioStocks, Inc. and Noctua Fund LP, and Form of 14% Notes Issued to Noctua (incorporated by reference to Exhibit 10.1 and Exhibit 10.2 of Current Report on Form 8-K dated May 8, 2009)
10.7
Note Exchange Agreement, dated as of May 29, 2009. (Incorporated by reference from Exhibit 10.7 to Current Report on Form 8-K, filed June 5, 2009)
10.8
Consulting agreement Heiner Dreismann (Incorporated by reference from Exhibit 10.1 to Current Report on Form 8-K, filed June 25, 2009).
10.9
Sponsored Research Agreement between the Company and The Regents of the University of California on behalf of Irvine campus, dated as of May 3, 2010.  (Incorporated by reference from Exhibit 10.1 to Current Report on Form 8-K, filed May 7, 2010)
10.10
Consortium Agreement among Academic Partners and Sponsors of the Micro/Nano Fluidics Fundamentals Focus MF3 Center, effective as of June 1, 2010. (Incorporated by reference from Exhibit 10.2 to Current Report on Form 8-K, filed May 7, 2010)
10.11
Consulting Agreement dated as of January 4, 2010, between the Company and Justin Heit. (Incorporated by reference from Exhibit 10.12 to Quarterly Report on Form 10Q for period ended March 31, 2010, filed May 24, 2010)
10.12
Consulting Agreement dated January 4, 2010, between the Company and OTC Investor Source, Inc. (Incorporated by reference from Exhibit 10.13to Quarterly Report on Form 10Q for period ended March 31, 2010, filed May 24, 2010)
10.13
Consulting Agreement dated as of February 15, 2010, between the Company and Andrew Simon. (Incorporated by reference from Exhibit 10.14 to Quarterly Report on Form 10Q for period ended March 31, 2010, filed May 24, 2010)
10.14
Consulting Agreement dated as of March 1, 2010, between the Company and Andrew Boll. (Incorporated by reference from Exhibit 10.15 to Quarterly Report on Form 10Q for period ended March 31, 2010, filed May 24, 2010)
10.15
Consulting Agreement, dated April 23, 2010, between the Company and Bruce Peterson. (Incorporated by reference from Exhibit 10.16 to Quarterly Report on Form 10Q for period ended March 31, 2010, filed May 24, 2010)
10.16
Sponsored Research Agreement, dated as of September 14, 2010, between Shrink Nanotechnologies, Inc. and University of California, Irvine.  (Incorporated by reference from  Exhibit 10.16 to Quarterly Report on Form 10Q for period ended September 20, 2010, filed November 29, 2010)
10.17
Scientific Advisory Board Consulting Agreement, between the Company and Dr. Sayantani Ghosh. (Incorporated by reference from Exhibit 10.17 to Quarterly Report on Form 10Q for period ended June 30, 2010, filed August 16, 2010)
10.18
Consulting Agreement between the Company and Equire, LLC. Business Financial Advisory. (Incorporated by reference from  Exhibit 10.16 to Quarterly Report on Form 10Q for period ended September 20, 2010, filed November 29, 2010)
10.19
Patent and Know-How License Agreement between Shrink Nanotechnologies, Inc. and Corning Incorporated, dated as of July 26, 2010. (Incorporated by reference from Exhibit 10.1 to Current Report on Form 8-K, Date of Event: July 26, 2010, filed October 18, 2010)
10.20
Lease Agreement between Shrink Nanotechnologies, Inc. and The University of California on behalf of Irvine campus, dated as of October 1, 2010.  (Incorporated by reference from Exhibit 10.2 to Current Report on Form 8-K, Date of Event: July 26, 2010, filed October 18, 2010)
31.1           Certification by Principal Executive Officer pursuant to Sarbanes Oxley Section 302.
32.1           Certification by Principal Executive Officer pursuant to 18 U.S.C. Section 1350.
 
 
 
 
 
 

 
 
Page 30

 


SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this Quarterly Report on Form 10-Q for the period ended September 30, 2010, to be signed on its behalf by the undersigned on May 23, 2011  thereunto duly authorized.

SHRINK NANOTECHNOLOGIES, INC.

     
 
By:  
/s/ Mark L. Baum
 
 
Name: Mark L. Baum
Title: President (Principal Executive Officer)
     
 
By:  
/s/ Mark L. Baum
 
 
Name: Mark L. Baum
Title: Vice Chairman (Principal Accounting Officer, Principal Financial Officer)
 


























 
Page 31